CUMULATIVE
SUPPLEMENT 9
SEP'99

APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

19TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF INFORMATION TECHNOLOGY
DIVISION OF DATA MANAGMENT AND SERVICES

1999

Prepared By
Division of Data Management and Services
Office of Information Technology
Center for Drug Evaluation and Research
Food and Drug Administration

Approved drug products with therapeutic equivalence
C:355661 M:174736 O:12937927

Available in March 2000

New 20th Edition

APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

20TH EDITION
2000

CONTENTS

- Prescription Drug Product List
- OTC Drug Product List
- Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List
- Discontinued Drug Product List
- Orphan Drug Product Designations
- Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution
- Patent and Exclusivity Information

See Subscription Form Inside Back Cover

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

19TH EDITION

Cumulative Supplement 9

SEPTEMBER 1999

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

19TH EDITION

CUMULATIVE SUPPLEMENT 9
SEPTEMBER 1999

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 19th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Patent and Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the patent and/or exclusivity expires. Refer to the Patent and Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Information regarding drug patents and exclusivity for an approved product will appear in this addendum as it is received and may not correspond with the month the drug product is approved and published in the Rx/OTC sections of the Cumulative Supplement.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

New additions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>DLT>** (DELETE) to the left of the line. The **>DLT>** symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements (hard copy only) for this edition.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 19th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 20th Edition.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
ASTRA PHARMACEUTICALS LP (ASTRA PHARMS)	ASTRA ZENECA LP (ASTRA ZENECA)
PENEDERM INC (PENEDERM)	BERTEK PHARMACEUTICALS (BERTEK PHARMS)
SANOFI PHARMACEUTICALS INC (SANOFI)	SANOFI SYNTHELABO INC (SANOFI SYNTHELABO)

1.3 DICLOFENAC SODIUM OPHTHALMIC SOLUTION 0.1%

Two NDAs have been approved for diclofenac sodium ophthalmic solution 0.1% (DSOS), (1) Ciba's NDA 20-037 for Voltaren and (2) Falcon Pharms' (Alcon) NDA 20-809 for DSOS. Alcon was required to do a study comparing their DSOS to Voltaren and to a placebo control in post cataract surgical inflammation. This study was necessary to demonstrate that the different formulation of the Alcon drug product did not affect the safety and/or effectiveness of the proposed drug product for this indication. Prior to the approval of Alcon's DSOS Ciba did clinical studies and was approved for two additional indications for the temporary relief of pain and photophobia in patients undergoing corneal refractive surgery. Three years of Waxman-Hatch marketing exclusivity was granted to Ciba for these two new uses.

Since the treatment of pain has a different site of action than the anti-inflammatory or photophobia indications the Agency did not have information to support a recommendation that the Alcon and Ciba DSOS are therapeutically equivalent for the treatment of pain. The designation of therapeutic equivalence at this time applies only to the anti-inflammatory indication. The therapeutic equivalence designation will apply to the photophobia indication upon expiration of Ciba's marketing exclusivity.

1.4 AVAILABILITY OF THE EDITION

The 19th Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800. The cost is $90.00 annually.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

There is an Electronic Orange Book Query (EOB) at http://www.fda.gov/cder/ob. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the annual edition or monthly cumulative supplements.

The Internet version of the hard copy Orange Book annual edition is at
http://www.fda.gov/cder/orange/adp.htm.

The Internet version of the hard copy monthly supplement is at
http://www.fda.gov/cder/orange/supplement/cspreface.htm. Changes to the annual edition are listed separately by month.

There are ASCII text files of the Orange Book drug product data at
http://www.fda.gov/cder/orange/obreadme.htm. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the annual edition or monthly cumulative supplements. Appendix A and Appendix B are updated quarterly.

The 19th annual edition of the 1998 Orange Book Patent and Exclusivity List is at
http://www.fda.gov/cder/orange/19bookpub.pdf.

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at
http://www.fda.gov/cder/orange/supplement/patents.pdf.

The current listing of the Orphan Product Designations and Approvals is available at
http://www.fda.gov/orphan/designat/list.htm.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1998) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1998	MAR 1999	JUN 1999	SEP 1999
DRUG PRODUCTS LISTED	9923	9975	10009	9939
SINGLE SOURCE	2504 (25.2%)	2520 (25.3%)	2523 (25.2%)	2257 (25.7%)
MULTISOURCE	7308 (73.6%)	7344 (73.6%)	7375 (73.7%)	7271 (73.2%)
THERAPEUTICALLY EQUIVALENT	6934 (69.9%)	6969 (69.9%)	7012 (70.1%)	6923 (69.7%)
NOT THERAPEUTICALLY EQUIVALENT	374 (3.8%)	375 (3.8%)	363 (3.6%)	348 (3.5%)
EXCEPTIONS[1]	111 (1.1%)	111 (1.1%)	111 (1.1%)	111 (1.1%)
NEW MOLECULAR ENTITIES APPROVED	10	3	5	13
NUMBER OF APPLICANTS	563	570	568	572

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

ACETAMINOPHEN; BUTALBITAL; CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN, CAPSULE

> DLT >				
> DLT >	AB	GRAHAM DM	325MG;50MG;40MG	N88758 001 MAR 27, 1985
> DLT >				
> ADD >		@ MALLINCKRODT	325MG;50MG;40MG	N88758 001 MAR 27, 1985
> ADD >				

FEMCET

AB	MALLINCKRODT	325MG;50MG;40MG	N89102 001 JUN 19, 1985
	@	325MG;50MG;40MG	N89102 001 JUN 19, 1985

TRIAD

AB	MALLINCKRODT	325MG;50MG;40MG	N89023 001 JUN 19, 1985
	@	325MG;50MG;40MG	N89023 001 JUN 19, 1985

ACETAMINOPHEN; BUTALBITAL; TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE

AB	WEST WARD	500MG;50MG;40MG	N40336 001 AUG 18, 1999

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

TABLET; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODONE BITARTRATE

+	MIKART	712.8MG;60MG;32MG	N40316 001 APR 28, 1999

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

ALLAY

AA	NORTON HN	500MG;5MG	N89907 001 JAN 13, 1989
AA	ZENITH GOLDLINE	500MG;5MG	N89907 001 JAN 13, 1989

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	MALLINCKRODT	500MG;5MG	N88956 001 JUL 19, 1985

ZYDONE

AA	MALLINCKRODT	500MG;5MG	N88956 001 JUL 19, 1985

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

AA	DURAMED	500MG;5MG	N40289 001 MAR 16, 1999

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

AA	AMIDE PHARM	325MG;5MG	N40203 001 MAR 15, 1999

PERCOCET

	ENDO PARMS	325MG;2.5MG	N40330 001 JUN 25, 1999
AA	ENDO PHARMS	325MG;5MG	N40330 002 JUN 25, 1999
+		325MG;2.5MG	N40330 001 JUN 25, 1999
+		500MG;7.5MG	N40341 001 JUL 26, 1999
+		650MG;10MG	N40341 002 JUL 26, 1999

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

PROPACET 100

AB	TEVA	650MG;100MG	N70107 001 JUN 12, 1985
	@	650MG;100MG	N70107 001 JUN 12, 1985

ACITRETIN

CAPSULE; ORAL

SORIATANE

	HLR	10MG	N19821 001 OCT 28, 1996
+		25MG	N19821 002 OCT 28, 1996
	ROCHE	10MG	N19821 001 OCT 28, 1996
+		25MG	N19821 002 OCT 28, 1996

ACYCLOVIR

CAPSULE; ORAL
ACYCLOVIR

AB	STASON	200MG	N75090 001 JAN 26, 1999	> DLT >	

TABLET; ORAL
ACYCLOVIR

AB	CARLSBAD	400MG	N75382 001 APR 30, 1999		
AB		800MG	N75382 002 APR 30, 1999		

ACYCLOVIR SODIUM

INJECTABLE; INJECTION
ACYCLOVIR

AP	ABBOTT	EQ 50MG BASE/ML	N75114 001 JUL 26, 1999		

ACYCLOVIR SODIUM

AP	+ AM PHARM PARTNERS	EQ 50MG BASE/ML	N74930 001 MAY 13, 1998		
	+	EQ 50MG BASE/ML	N74930 001 MAY 13, 1998		
AP	MERIDIAN MEDCL TECHN	EQ 50MG BASE/ML	N75065 001 FEB 25, 1999		

ALBUTEROL

AEROSOL, METERED; INHALATION
ALBUTEROL

AB	MEDEVA	0.09MG/INH	N72273 001 AUG 14, 1996		
AB	MEDEVA PHARMS MA	0.09MG/INH	N72273 001 AUG 14, 1996		

ALBUTEROL SULFATE

SOLUTION; INHALATION
ALBUTEROL SULFATE

AN	HI TECH PHARMA	EQ 0.083% BASE	N75063 001 FEB 09, 1999		

SYRUP; ORAL
ALBUTEROL SULFATE

AA	UDL	EQ 2MG BASE/5ML	N75262 001 MAR 30, 1999		

ALBUTEROL SULFATE

SYRUP; ORAL
VENTOLIN

AA	+ GLAXO WELLCOME	EQ 2MG BASE/5ML	N19621 001 JUN 10, 1987	> DLT >	
	@	EQ 2MG BASE/5ML	N19621 001 JUN 10, 1987	> ADD >	

ALCOHOL; DEXTROSE

INJECTABLE; INJECTION
ALCOHOL 5% IN DEXTROSE 5% IN WATER

AP	BAXTER HLTHCARE	5ML/100ML;5GM/100ML	N83256 001	> DLT >	
	@	5ML/100ML;5GM/100ML	N83256 001	> ADD >	

ALITRETINOIN

GEL; TOPICAL
PANRETIN

	+ LIGAND	EQ 0.1% BASE	N20886 001 FEB 02, 1999		

ALLOPURINOL

TABLET; ORAL
ZYLOPRIM

AB	FARO PHARMS	100MG	N16084 001		
AB	+	300MG	N16084 002		
AB	GLAXO WELLCOME	100MG	N16084 001		
AB	+	300MG	N16084 002		

ALLOPURINOL SODIUM

INJECTABLE; INJECTION
ALOPRIM

	+ CATALYTICA PHARMS	EQ 500MG BASE/VIAL	N20298 001 MAY 17, 1996	> ADD >	

ZYLOPRIM

	+ CATALYTICA PHARMS	EQ 500MG BASE/VIAL	N20298 001 MAY 17, 1996	> DLT >	

ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN, D-; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A

INJECTABLE; INJECTION
CERNEVIT-12
\+ BAXTER HLTHCARE — 11.2 IU/VIAL;125MG/VIAL;60 UGM/VIAL; 200 IU/VIAL;5.5MG/VIAL;414 UGM/VIAL; 46MG/VIAL;17.25MG/VIAL;4.53MG/VIAL; 4.14MG/VIAL;3.51MG/VIAL; 3,500 IU/VIAL — N20924 001 APR 06, 1999

ALPRAZOLAM

CONCENTRATE; ORAL
ALPRAZOLAM
ROXANE — 1MG/ML — N74312 001 OCT 31, 1993
\+ — 1MG/ML — N74312 001 OCT 31, 1993

SOLUTION; ORAL
ALPRAZOLAM
ROXANE — 0.5MG/5ML — N74314 001 OCT 31, 1993 >ADD<
\+ — 0.5MG/5ML — N74314 001 OCT 31, 1993 >ADD<

TABLET; ORAL
ALPRAZOLAM
AB ALPHAPHARM — **2MG** — **N74046 004** MAY 07, 1997

ALPROSTADIL

INJECTABLE; INJECTION
ALPROSTADIL
AP GENSIA SICOR PHARMS — **0.5MG/ML** — **N75196 001** APR 30, 1999

AMCINONIDE

CREAM; TOPICAL
CYCLOCORT
@ FUJISAWA HLTHCARE — 0.025% — N18116 001

AMCINONIDE

CREAM; TOPICAL
CYCLOCORT
\+ FUJISAWA HLTHCARE — 0.1% — N18116 002
LEDERLE — 0.025% — N18116 001
\+ — 0.1% — N18116 002

LOTION; TOPICAL
CYCLOCORT
\+ FUJISAWA HLTHCARE — 0.1% — N19729 001 JUN 13, 1988
\+ LEDERLE — 0.1% — N19729 001 JUN 13, 1988

OINTMENT; TOPICAL
CYCLOCORT
\+ FUJISAWA HLTHCARE — 0.1% — N18498 001
\+ WYETH AYERST — 0.1% — N18498 001

AMIFOSTINE

INJECTABLE; INJECTION
ETHYOL
US BIOSCIENCE — 375MG/VIAL — N20221 002 SEP 10, 1999

AMINO ACIDS

INJECTABLE; INJECTION
AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE
FRESENIUS KABI — 5.2% — N18901 001 APR 06, 1984
PHARMACIA AND UPJOHN — 5.2% — N18901 001 APR 06, 1984

NEOPHAM 6.4%
@ FRESENIUS KABI — 6.4% — N18792 001 JAN 17, 1984
@ PHARMACIA AND UPJOHN — 6.4% — N18792 001 JAN 17, 1984

NOVAMINE 11.4%
FRESENIUS KABI — 11.4% — N17957 003 AUG 09, 1982
PHARMACIA AND UPJOHN — 11.4% — N17957 003 AUG 09, 1982

NOVAMINE 15%
FRESENIUS KABI — 15% — N17957 004 NOV 28, 1986

AMINO ACIDS

INJECTABLE; INJECTION
NOVAMINE 15%
PHARMACIA AND UPJOHN 15% N17957 004 NOV 28, 1986

NOVAMINE 8.5%
@ FRESENIUS KABI 8.5% N17957 002 AUG 09, 1982
@ PHARMACIA AND UPJOHN 8.5% N17957 002 AUG 09, 1982

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE; INJECTION
VEINAMINE 8%
@ FRESENIUS KABI 8%;61MG/100ML;211MG/100ML; 56MG/100ML;388MG/100ML N17957 001
@ PHARMACIA AND UPJOHN 8%;61MG/100ML;211MG/100ML; 56MG/100ML;388MG/100ML N17957 001

AMINOPHYLLINE

INJECTABLE; INJECTION
AMINOPHYLLINE
AP SMITH AND NEPHEW **25MG/ML** **N88749 001 MAY 30, 1985**
@ 25MG/ML N88749 001 MAY 30, 1985

AMIODARONE HYDROCHLORIDE

TABLET; ORAL
AMIODARONE HCL
AB ALPHAPHARM **200MG** **N75188 001 FEB 24, 1999**
AB NOVOPHARM **200MG** **N74895 001 APR 16, 1999**

AMITRIPTYLINE HYDROCHLORIDE

INJECTABLE; INJECTION
AMITRIPTYLINE HCL
AP STERIS **10MG/ML** **N85594 001**

AMITRIPTYLINE HYDROCHLORIDE

INJECTABLE; INJECTION
AMITRIPTYLINE HCL
@ STERIS 10MG/ML N85594 001
ELAVIL
AP + ZENECA **10MG/ML** **N12704 001**
\+ 10MG/ML N12704 001

TABLET; ORAL
AMITRIPTYLINE HCL
BP COPLEY PHARM 10MG N88421 001 APR 30, 1984
BP 25MG N88422 001 APR 30, 1984
BP 50MG N88423 001 APR 30, 1984
BP 75MG N88424 001 APR 30, 1984
BP 100MG N88425 001 APR 30, 1984
BP 150MG N88426 001 APR 30, 1984
@ 10MG N88421 001 APR 30, 1984
@ 25MG N88422 001 APR 30, 1984
@ 50MG N88423 001 APR 30, 1984
@ 75MG N88424 001 APR 30, 1984
@ 100MG N88425 001 APR 30, 1984
@ 150MG N88426 001 APR 30, 1984

ENDEP
AB ROCHE **10MG** **N83639 001**
AB **25MG** **N83639 002**
AB **50MG** **N83639 003**
AB **75MG** **N83639 004**
AB **100MG** **N83639 005**
@ 10MG N83639 001
@ 25MG N83639 002
@ 50MG N83639 003
@ 75MG N83639 004
@ 100MG N83639 005

AMOXICILLIN

CAPSULE; ORAL
AMOXICILLIN

AB	RANBAXY	250MG	N65016 001	APR 08, 1999
AB		500MG	N65016 002	APR 08, 1999

POWDER FOR RECONSTITUTION; ORAL
AMOXIL

	SMITHKLINE BEECHAM	200MG/5ML	N50760 001	APR 15, 1999
+		400MG/5ML	N50760 002	APR 15, 1999

TABLET, CHEWABLE; ORAL
AMOXIL

	SMITHKLINE BEECHAM	200MG	N50761 001	APR 15, 1999
+		400MG	N50761 002	APR 15, 1999

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX; INJECTION
AMPHOTEC

+	ALZA	50MG/VIAL	N50729 001	NOV 22, 1996
+		100MG/VIAL	N50729 002	NOV 22, 1996
+	SEQUUS	50MG/VIAL	N50729 001	NOV 22, 1996
+		100MG/VIAL	N50729 002	NOV 22, 1996

AMPRENAVIR

CAPSULE; ORAL
AGENERASE

	GLAXO WELLCOME	50MG	N21007 001	APR 15, 1999
+		150MG	N21007 002	APR 15, 1999

SOLUTION; ORAL
AGENERASE

+	GLAXO WELLCOME	15MG/ML	N21039 001	APR 15, 1999

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION
KABIVITE PED F + W KIT

+	FRESENIUS KABI	N/A,80MG/VIAL;N/A,0.02MG/VIAL;N/A,0.001MG/VIAL;400 IU/10ML,N/A;N/A,0.14MG/VIAL;N/A,17MG/VIAL;N/A,5MG/VIAL;0.2MG/10ML,N/A;N/A,1MG/VIAL;N/A,1.4MG/VIAL;N/A,1.2MG/VIAL;EQ 2,300 UNITS BASE/10ML,N/A;7 IU/10ML,N/A	N20176 001	DEC 29, 1993
+	PHARMACIA AND UPJOHN	N/A,80MG/VIAL;N/A,0.02MG/VIAL;N/A,0.001MG/VIAL;400 IU/10ML,N/A;N/A,0.14MG/VIAL;N/A,17MG/VIAL;N/A,5MG/VIAL;0.2MG/10ML,N/A;N/A,1MG/VIAL;N/A,1.4MG/VIAL;N/A,1.2MG/VIAL;EQ 2,300 UNITS BASE/10ML,N/A;7 IU/10ML,N/A	N20176 001	DEC 29, 1993

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

AB	ENDO PHARMS	325MG;50MG;40MG;30MG	N75351 001	MAR 05, 1999

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

AB	STEVENS J	385MG;30MG;25MG	N74988 001	APR 30, 1999
AB		770MG;60MG;50MG	N74988 002	APR 30, 1999

ASTEMIZOLE

TABLET; ORAL
HISMANAL

+	JANSSEN	10MG	N19402 001	DEC 29, 1988

ATENOLOL

TABLET; ORAL
ATENOLOL

	AB	APOTHECON	50MG	N73317 001	
				MAR 20, 1992	
	AB		100MG	N73318 001	
				MAR 20, 1992	
		@	50MG	N73317 001	> ADD >
				MAR 20, 1992	> ADD >
		@	100MG	N73318 001	
				MAR 20, 1992	
> ADD >		MYLAN	25MG	N73457 002	
> ADD >				APR 26, 1999	

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL
DIPHENOXYLATE HCL AND ATROPINE SULFATE

> DLT >	AA	PHARMERAL	0.025MG;2.5MG	N85035 001
> ADD >	AA	R AND S PHARMA	0.025MG;2.5MG	N85035 001

DIPHENOXYLATE HCL W/ ATROPINE SULFATE

	AA	ZENITH GOLDLINE	0.025MG;2.5MG	N86727 001
		@	0.025MG;2.5MG	N86727 001

AZATHIOPRINE

TABLET; ORAL
AZATHIOPRINE

	AB	APPLIED ANAL	50MG	N75252 001
				JUN 07, 1999

IMURAN

	AB +	FARO PHARMS	50MG	N16324 001
		@	25MG	N16324 002
> ADD >	AB +	GLAXO WELLCOME	50MG	N16324 001
> DLT >		@	25MG	N16324 002

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION
IMURAN

AP	+	FARO PHARMS	EQ 100MG BASE/VIAL	N17391 001
AP	+	GLAXO WELLCOME	EQ 100MG BASE/VIAL	N17391 001

AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE

POWDER FOR RECONSTITUTION, TABLET; ORAL
TROVAN/ZITHROMAX COMPLIANCE PAK

> DLT >	+	PFIZER	EQ 1GM BASE,N/A;N/A, EQ 100MG BASE	N50762 001
> DLT >				DEC 18, 1998
> DLT >		@	EQ 1GM BASE,N/A;N/A, EQ 100MG BASE	N50762 001
> ADD >				DEC 18, 1998

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

AT	+	ALTANA	400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N60731 002
		@	400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N60731 002
AT		PHARMADERM	400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N62166 002
	+		400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N62166 002

BENDROFLUMETHIAZIDE; NADOLOL

TABLET; ORAL
CORZIDE

		APOTHECON	5MG;40MG	N18647 001
				MAY 25, 1983
	+		5MG;80MG	N18647 002
				MAY 25, 1983
		BRISTOL MYERS SQUIBB	5MG;40MG	N18647 001
				MAY 25, 1983
	+		5MG;80MG	N18647 002
				MAY 25, 1983

BENZYL PENICILLOYL-POLYLYSINE

INJECTABLE; INJECTION
PRE-PEN

+	BAYER	60 UMOLAR	N50114 001
+	HOLLISTER STIER LABS	60 UMOLAR	N50114 001

BETAMETHASONE DIPROPIONATE

OINTMENT, AUGMENTED; TOPICAL
BETAMETHASONE DIPROPIONATE

AB	ALTANA	**EQ 0.05% BASE**	**N75373 001**	
			JUN 22, 1999	

BETAMETHASONE VALERATE

AEROSOL; TOPICAL
LUXIQ

+	CONNETICS	EQ 0.12% BASE	N20934 001	
			FEB 28, 1999	> ADD >

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
WELLBUTRIN

+	GLAXO WELLCOME	50MG	N20358 001	
			OCT 04, 1996	> ADD >
+		100MG	N20358 002	
			OCT 04, 1996	> ADD >
+		150MG	N20358 003	
			OCT 04, 1996	> ADD >

WELLBUTRIN SR

+	GLAXO WELLCOME	50MG	N20358 001	
			OCT 04, 1996	
+		100MG	N20358 002	
			OCT 04, 1996	
+		150MG	N20358 003	
			OCT 04, 1996	

BUSULFAN

INJECTABLE; INJECTION
BUSULFEX

+	ORPHAN MEDCL	6MG/ML	N20954 001	
			FEB 04, 1999	

BUTOCONAZOLE NITRATE

CREAM; VAGINAL
FEMSTAT

+	SYNTEX	2%	N19215 001	
			NOV 25, 1985	

BUTOCONAZOLE NITRATE

CREAM; VAGINAL
FEMSTAT

@	SYNTEX	2%	N19215 001	
			NOV 25, 1985	

FEMSTAT ONE

+	KV PHARM	2%	N19881 001	
			FEB 07, 1997	
+	SYNTEX	2%	N19881 001	
			FEB 07, 1997	

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS, ORAL
CAFCIT

+	OPR DEVELOP LP	EQ 10MG BASE/ML	N20793 001	
			SEP 21, 1999	

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION
ENDOSOL EXTRA

AT	AKORN	**0.154MG/ML;0.92MG/ML;0.184MG/ML; 0.2MG/ML;0.38MG/ML;2.1MG/ML; 7.14MG/ML;0.42MG/ML**	**N20079 001**
			NOV 27, 1991
AT	ALLERGAN	**0.154MG/ML;0.92MG/ML;0.184MG/ML; 0.2MG/ML;0.38MG/ML;2.1MG/ML; 7.14MG/ML;0.42MG/ML**	**N20079 001**
			NOV 27, 1991

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	37MG/100ML;5GM/100ML;31MG/100ML; 120MG/100ML;330MG/100ML; 88MG/100ML	N18271 001
@		37MG/100ML;5GM/100ML;31MG/100ML; 120MG/100ML;330MG/100ML; 88MG/100ML	N18271 001

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION
ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	35MG/100ML;5GM/100ML;30MG/100ML; 74MG/100ML;640MG/100ML;500MG/100ML; 74MG/100ML	N18269 002 JAN 17, 1983	
@		35MG/100ML;5GM/100ML;30MG/100ML; 74MG/100ML;640MG/100ML;500MG/100ML; 74MG/100ML	N18269 002 JAN 17, 1983	

CAPECITABINE

TABLET; ORAL
XELODA

	HLR	150MG	N20896 001 APR 30, 1998	> ADD >
	ROCHE	150MG	N20896 001 APR 30, 1998	> ADD >
				> ADD >
				> ADD >
				> ADD >
				> DLT >
				> DLT >

CAPTOPRIL

TABLET; ORAL
CAPTOPRIL

AB	BAKER NORTON	12.5MG	N74590 004 AUG 30, 1996
AB		25MG	N74590 002 AUG 30, 1996
AB		50MG	N74590 001 AUG 30, 1996
AB		100MG	N74590 003 AUG 30, 1996
AB	ZENITH GOLDLINE	12.5MG	N74590 004 AUG 30, 1996
AB		25MG	N74590 002 AUG 30, 1996
AB		50MG	N74590 001 AUG 30, 1996
AB		100MG	N74590 003 AUG 30, 1996

CARBENICILLIN DISODIUM

INJECTABLE; INJECTION
GEOPEN

+	ROERIG	EQ 1GM BASE/VIAL	N50306 001
+		EQ 2GM BASE/VIAL	N50306 004
+		EQ 5GM BASE/VIAL	N50306 002
+		EQ 10GM BASE/VIAL	N50306 006
+		EQ 30GM BASE/VIAL	N50306 007
@		EQ 1GM BASE/VIAL	N50306 001
@		EQ 2GM BASE/VIAL	N50306 004
@		EQ 5GM BASE/VIAL	N50306 002
@		EQ 10GM BASE/VIAL	N50306 006
@		EQ 30GM BASE/VIAL	N50306 007

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL
CARBIDOPA AND LEVODOPA

AB		MYLAN	50MG;200MG	N75091 001 SEP 30, 1999

SINEMET CR

AB	+	DUPONT PHARMS	50MG;200MG	N19856 001 MAY 30, 1991
	+		50MG;200MG	N19856 001 MAY 30, 1991

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
OCUPRESS

+	CIBA	1%	N19972 001 MAY 23, 1990
+	OTSUKA	1%	N19972 001 MAY 23, 1990

CEFACLOR

CAPSULE; ORAL
CEFACLOR

AB	LEDERLE	EQ 250MG BASE	N64107 001 APR 27, 1995
AB		EQ 500MG BASE	N64107 002 APR 27, 1995
@		EQ 250MG BASE	N64107 001 APR 27, 1995

CEFACLOR

CAPSULE; ORAL

	CEFACLOR			> ADD >	
	@ LEDERLE	EQ 500MG BASE	N64107 002 APR 27, 1995	> ADD >	
AB	TEVA	**EQ 250MG BASE**	**N64081 001** SEP 16, 1996	> DLT >	
AB		**EQ 500MG BASE**	**N64081 002** SEP 16, 1996	> DLT >	
	@	EQ 250MG BASE	N64081 001 SEP 16, 1996	> ADD >	
	@	EQ 500MG BASE	N64081 002 SEP 16, 1996	> ADD >	

POWDER FOR RECONSTITUTION; ORAL

	CEFACLOR				
AB	LEDERLE	**EQ 125MG BASE/5ML**	**N64114 001** APR 28, 1995	> DLT >	
AB		**EQ 187MG BASE/5ML**	**N64115 001** APR 28, 1995	> DLT >	
AB		**EQ 250MG BASE/5ML**	**N64116 001** APR 28, 1995	> ADD >	
AB		**EQ 375MG BASE/5ML**	**N64110 001** APR 28, 1995	> ADD >	
	@	EQ 125MG BASE/5ML	N64114 001 APR 28, 1995		
	@	EQ 187MG BASE/5ML	N64115 001 APR 28, 1995		
	@	EQ 250MG BASE/5ML	N64116 001 APR 28, 1995		
	@	EQ 375MG BASE/5ML	N64110 001 APR 28, 1995		

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

	CEFADROXIL				
AB	BARR	**EQ 500MG BASE**	**N65015 001** JUN 22, 1999		

POWDER FOR RECONSTITUTION; ORAL

> DLT >	**CEFADROXIL**				
> DLT > **AB**	APOTHECON	**EQ 125MG BASE/5ML**	**N62334 001**		
> DLT > **AB**		**EQ 250MG BASE/5ML**	**N62334 002**		
> DLT > **AB**		**EQ 500MG BASE/5ML**	**N62334 003**		
> ADD >	@	EQ 125MG BASE/5ML	N62334 001		
> ADD >	@	EQ 250MG BASE/5ML	N62334 002		

CEFADROXIL/CEFADROXIL HEMIHYDRATE

POWDER FOR RECONSTITUTION; ORAL

	CEFADROXIL				
	@ APOTHECON	EQ 500MG BASE/5ML	N62334 003		
	DURICEF				
AB +	BRISTOL MYERS SQUIBB	**EQ 125MG BASE/5ML**	**N50527 002**		
AB +		**EQ 250MG BASE/5ML**	**N50527 003**		
AB +		**EQ 500MG BASE/5ML**	**N50527 001**		
+		EQ 125MG BASE/5ML	N50527 002		
+		EQ 250MG BASE/5ML	N50527 003		
+		EQ 500MG BASE/5ML	N50527 001		

TABLET; ORAL

	CEFADROXIL				
AB	RANBAXY	**EQ 1GM BASE**	**N65018 001** APR 23, 1999		
	ULTRACEF				
AB	APOTHECON	**EQ 1GM BASE**	**N62390 001** JUN 10, 1982		
	@	EQ 1GM BASE	N62390 001 JUN 10, 1982		

CEFTAZIDIME (ARGININE FORMULATION)

INJECTABLE; INJECTION

	CEPTAZ				
AP +	GLAXO WELLCOME	**1GM/VIAL**	**N50646 002** SEP 27, 1990		
AP +		**2GM/VIAL**	**N50646 003** SEP 27, 1990		
AP +		**10GM/VIAL**	**N50646 004** SEP 27, 1990		
+		1GM/VIAL	N50646 002 SEP 27, 1990		
+		2GM/VIAL	N50646 003 SEP 27, 1990		
+		10GM/VIAL	N50646 004 SEP 27, 1990		
	PENTACEF				
AP	SMITHKLINE BEECHAM	**1GM/VIAL**	**N63322 001** NOV 07, 1995		
AP		**1GM/VIAL**	**N64006 001** MAR 31, 1992		
AP		**2GM/VIAL**	**N63322 002** NOV 07, 1995		
AP		**2GM/VIAL**	**N64006 002** MAR 31, 1992		

CEFTAZIDIME (ARGININE FORMULATION)

INJECTABLE; INJECTION

	PENTACEF			
AP	SMITHKLINE BEECHAM	**10GM/VIAL**	**N64008 002**	**MAR 31, 1992**
		6GM/VIAL	**N64008 001**	**MAR 31, 1992**
	@	1GM/VIAL	N63322 001	NOV 07, 1995
	@	1GM/VIAL	N64006 001	MAR 31, 1992
	@	2GM/VIAL	N63322 002	NOV 07, 1995
	@	2GM/VIAL	N64006 002	MAR 31, 1992
	@	6GM/VIAL	N64008 001	MAR 31, 1992
	@	10GM/VIAL	N64008 002	MAR 31, 1992

CEPHALEXIN

CAPSULE; ORAL

		CEPHALEXIN			
>ADD>	**AB**	RANBAXY	**EQ 250MG BASE**	**N65007 001**	SEP 16, 1999
>ADD>					
>ADD>	**AB**		**EQ 500MG BASE**	**N65007 002**	SEP 16, 1999
>ADD>					

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION

	CEPHALOTHIN SODIUM			
AP	ABBOTT	**EQ 1GM BASE/VIAL**	**N62547 001**	**SEP 11, 1985**
AP		**EQ 2GM BASE/VIAL**	**N62547 002**	**SEP 11, 1985**
	@	EQ 1GM BASE/VIAL	N62547 001	SEP 11, 1985
	@	EQ 2GM BASE/VIAL	N62547 002	SEP 11, 1985

CERIVASTATIN SODIUM

TABLET; ORAL

		BAYCOL			
	+	BAYER	0.3MG	N20740 004	JUN 26, 1997
			0.3MG	N20740 004	JUN 26, 1997
	+		0.4MG	N20740 005	MAY 24, 1999

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

		A-POXIDE			
	@	ABBOTT	5MG	**N85517 001**	
	@		5MG	N85517 001	
		CHLORDIAZEPOXIDE HCL			
>DLT> **AB**		MAST MM	**10MG**	**N86217 001**	
>ADD>	@		10MG	N86217 001	

CHLOROQUINE PHOSPHATE

TABLET; ORAL

		CHLOROQUINE PHOSPHATE			
>DLT> **AA**		MD PHARM	**EQ 150MG BASE**	**N87228 001**	
>ADD>	@		EQ 150MG BASE	N87228 001	
>ADD> **AA**		WEST WARD	**EQ 300MG BASE**	**N83082 002**	SEP 17, 1999
>ADD>					

CHLOROTRIANISENE

CAPSULE; ORAL

		CHLOROTRIANISENE			
AA		BANNER PHARMACAPS	**12MG**	**N84652 001**	
	@		12MG	N84652 001	
		TACE			
AA	+	HOECHST MARION RSSL	**12MG**	**N08102 004**	
	+		12MG	N08102 004	

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

	CHLORPROMAZINE HCL			
AA	PHARM ASSOC	**100MG/ML**	**N40224 001**	JAN 26, 1999

CHOLESTYRAMINE

POWDER; ORAL

	CHOLESTYRAMINE			
AB	BAKER NORTON	EQ 4GM RESIN/PACKET	N74771 001	JUL 09, 1997
AB		EQ 4GM RESIN/SCOOPFUL	N74771 002	JUL 09, 1997
AB	ZENITH GOLDLINE	EQ 4GM RESIN/PACKET	N74771 001	JUL 09, 1997
AB		EQ 4GM RESIN/SCOOPFUL	N74771 002	JUL 09, 1997
	CHOLESTYRAMINE LIGHT			
AB	COPLEY PHARM	EQ 4GM RESIN/SCOOPFUL	N74555 002	SEP 30, 1998

CHYMOTRYPSIN

POWDER FOR RECONSTITUTION; OPHTHALMIC

	CATARASE			
	+ CIBA	300 UNITS/VIAL	N16938 001	
	@	300 UNITS/VIAL	N16938 001	
	ZOLYSE			
	ALCON	750 UNITS/VIAL	N11903 001	
	+	750 UNITS/VIAL	N11903 001	

CILOSTAZOL

TABLET; ORAL

	PLETAL			
	OTSUKA	50MG	N20863 001	JAN 15, 1999
	+	100MG	N20863 002	JAN 15, 1999

CISPLATIN

INJECTABLE; INJECTION

	CISPLATIN			
AP	AM PHARM PARTNERS	1MG/ML	N74735 001	JUL 16, 1999
	PLATINOL-AQ			
AP	+ BRISTOL MYERS	1MG/ML	N18057 004	NOV 08, 1988
	+	1MG/ML	N18057 004	NOV 08, 1988

CLARITHROMYCIN

GRANULE, FOR RECONSTITUTION; ORAL

	BIAXIN			
	ABBOTT	187MG/5ML	N50698 003	SEP 30, 1998

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

	CLEOCIN HCL			
AB	+ PHARMACIA AND UPJOHN	EQ 75MG BASE	N50162 001	
AB		EQ 75MG BASE	N50162 001	
AB	+	EQ 150MG BASE	N50162 002	
AB		EQ 150MG BASE	N50162 002	
		EQ 300MG BASE	N50162 003	APR 14, 1988
	+	EQ 300MG BASE	N50162 003	APR 14, 1988

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

	CLINDAMYCIN PHOSPHATE			
AP	SOLOPAK	EQ 150MG BASE/ML	N62819 001	MAR 15, 1988
AP		EQ 150MG BASE/ML	N62852 001	MAR 17, 1988
	@	EQ 150MG BASE/ML	N62819 001	MAR 15, 1988
	@	EQ 150MG BASE/ML	N62852 001	MAR 17, 1988
AP	STERIS	EQ 150MG BASE/ML	N62900 001	JUN 08, 1988
AP		EQ 150MG BASE/ML	N63079 001	MAR 05, 1990
	@	EQ 150MG BASE/ML	N62900 001	JUN 08, 1988
	@	EQ 150MG BASE/ML	N63079 001	MAR 05, 1990

SUPPOSITORY; VAGINAL

	CLEOCIN			
	+ PHARMACIA AND UPJOHN	100MG	N50767 001	AUG 13, 1999

CLOBETASOL PROPIONATE

CREAM; TOPICAL

	CLOBETASOL PROPIONATE		
AB	ALPHARMA US PHARM	0.05%	N74139 001 AUG 03, 1994
AB	NMC	0.05%	N74139 001 AUG 03, 1994
	CLOBETASOL PROPIONATE (EMOLLIENT)		
AB2	ALTANA	0.05%	N75430 001 MAY 26, 1999
	@	0.05%	N75430 001 MAY 26, 1999

GEL; TOPICAL

	CLOBETASOL PROPIONATE		
AB	TARO	0.05%	N75279 001 MAY 28, 1999

SOLUTION; TOPICAL

	CLOBETASOL PROPIONATE		
AT	ALTANA	0.05%	N75391 001 FEB 08, 1999

CLOMIPHENE CITRATE

TABLET; ORAL

	CLOMIPHENE CITRATE		
AB	PAR PHARM	50MG	N75528 001 AUG 30, 1999

CLOXACILLIN SODIUM

CAPSULE; ORAL

	CLOXAPEN		
AB	SMITHKLINE BEECHAM	EQ 250MG BASE	N62233 001
AB		EQ 500MG BASE	N62233 002
	@	EQ 250MG BASE	N62233 001
	@	EQ 500MG BASE	N62233 002

POWDER FOR RECONSTITUTION; ORAL

	CLOXACILLIN SODIUM		
AA	TEVA	EQ 125MG BASE/5ML	N62268 001
	@	EQ 125MG BASE/5ML	N62268 001
	+		
	TEGOPEN		
AA	+ APOTHECON	EQ 125MG BASE/5ML	N61453 001
	@	EQ 125MG BASE/5ML	N61453 001

CLOZAPINE

TABLET; ORAL

	CLOZAPINE		
AB	CREIGHTON	25MG	N74546 001 AUG 30, 1996
AB		100MG	N74546 002 AUG 30, 1996
AB	GENEVA PHARMS	25MG	N74546 001 AUG 30, 1996
AB		100MG	N74546 002 AUG 30, 1996
AB	MYLAN	25MG	N75417 001 MAY 27, 1999
AB		100MG	N75417 002 MAY 27, 1999

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

	COLISTIMETHATE		
AP	PHARMA TEK	EQ 150MG BASE/VIAL	N64216 001 FEB 26, 1999
	COLY-MYCIN M		
AP	+ PARKEDALE	EQ 150MG BASE/VIAL	N50108 002
	+	EQ 150MG BASE/VIAL	N50108 002

CORTICOTROPIN

INJECTABLE; INJECTION

	CORTICOTROPIN		
AP	+ STERIS	40 UNITS/VIAL	N88772 001 NOV 21, 1984
	@	40 UNITS/VIAL	N88772 001 NOV 21, 1984

CROMOLYN SODIUM

CAPSULE; ORAL

	GASTROCROM		
	+ MEDEVA	100MG	N19188 001 DEC 22, 1989
	@	100MG	N19188 001 DEC 22, 1989

CROMOLYN SODIUM

SOLUTION; INHALATION
CROMOLYN SODIUM

AN	ALPHARMA	10MG/ML	N75067 001	
			JUL 19, 1999	
> ADD > AN	ROXANE	10MG/ML	N75175 001	> ADD >
> ADD >			SEP 30, 1999	> ADD >

SOLUTION/DROPS; OPHTHALMIC
CROMOLYN SODIUM

AT	ALCON	4%	N75282 001
			JUN 16, 1999

CROMOPTIC

AT	KING PHARMS	4%	N75088 001
			APR 27, 1999

CROTAMITON

LOTION; TOPICAL
CROTAN

> DLT > AT	GALDERMA	10%	N87204 001
> ADD > AT	SUMMERS	10%	N87204 001

CYANOCOBALAMIN

INJECTABLE; INJECTION
RUVITE

> DLT >			
> DLT > AP	SAVAGE LABS	1MG/ML	N80570 002
> ADD >	@	1MG/ML	N80570 002

CYCLOPHOSPHAMIDE

TABLET; ORAL
CYCLOPHOSPHAMIDE

AB	ROXANE	25MG	N40032 001
			AUG 17, 1999
AB		50MG	N40032 002
			AUG 17, 1999

CYTOXAN

AB	BRISTOL MYERS SQUIBB	25MG	N12141 002	> ADD >
AB	+	50MG	N12141 001	
		25MG	N12141 002	> ADD >
	+	50MG	N12141 001	> ADD >
				> ADD >
				> ADD >
				> ADD >

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL
CYPROHEPTADINE HCL

> DLT > AA	MD PHARM	4MG	N87566 001
			NOV 10, 1982
> DLT >			
> ADD >	@	4MG	N87566 001
> ADD >			NOV 10, 1982

CYSTEINE HYDROCHLORIDE

INJECTABLE; INJECTION
CYSTEINE HCL

	@ FRESENIUS KABI	7.25%	N19523 001
			OCT 22, 1986
	@ PHARMACIA AND UPJOHN	7.25%	N19523 001
			OCT 22, 1986

CYTARABINE

INJECTABLE, LIPOSOMAL; INJECTION
DEPOCYT

	+ DEPOTECH	10MG/ML	N21041 001
			APR 01, 1999
	+ SKYEPHARMA	10MG/ML	N21041 001
			APR 01, 1999

DACARBAZINE

INJECTABLE; INJECTION
DACARBAZINE

AP	AM PHARM PARTNERS	100MG/VIAL	N75371 001
			AUG 27, 1999
AP		200MG/VIAL	N75371 002
			AUG 27, 1999

DTIC-DOME

AP	+ BAYER	100MG/VIAL	N17575 001
	+	100MG/VIAL	N17575 001

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE; INJECTION
SYNERCID

RHONE POULENC RORER	350MG/VIAL; EQ 150MG BASE/VIAL	N50747 001
		SEP 21, 1999

> ADD > DALFOPRISTIN; QUINUPRISTIN

> ADD > INJECTABLE; INJECTION
> ADD > SYNERCID
> ADD > RHONE POULENC RORER 350MG/VIAL; EQ 150MG BASE/VIAL N50748 001 SEP 21, 1999
> ADD >
> ADD >

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

CERUBIDINE

AP	+ BEDFORD	EQ 20MG BASE/VIAL	N64103 001 FEB 03, 1995
	+	EQ 20MG BASE/VIAL	N64103 001 FEB 03, 1995

DAUNORUBICIN HCL

AP	BIGMAR	EQ 20MG BASE/VIAL	N65000 001 MAY 25, 1999

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL

DDAVP

AB	+ RHONE POULENC RORER	0.01MG/SPRAY	N17922 003 AUG 07, 1996
	+	0.01MG/SPRAY	N17922 003 AUG 07, 1996

DESMOPRESSIN ACETATE

AB	BAUSCH AND LOMB	0.01MG/SPRAY	N74830 001 JAN 25, 1999

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21

DESOGESTREL AND ETHINYL ESTRADIOL

AB	DURAMED	0.15MG;0.03MG	N75256 001 AUG 12, 1999

ORTHO-CEPT

AB	+ JOHNSON RW	0.15MG;0.03MG	N20301 001 DEC 14, 1992
	+	0.15MG;0.03MG	N20301 001 DEC 14, 1992

TABLET; ORAL-28

DESOGESTREL AND ETHINYL ESTRADIOL

AB	DURAMED	0.15MG;0.03MG	N75256 002 AUG 12, 1999

DESONIDE

CREAM; TOPICAL

TRIDESILON

> DLT >	AB	+ BAYER	0.05%	N17010 001
> ADD >	AB	+ CLAY PARK	0.05%	N17010 001

OINTMENT; TOPICAL

TRIDESILON

> DLT >	AB	+ BAYER	0.05%	N17426 001
> ADD >	AB	+ CLAY PARK	0.05%	N17426 001

DEXAMETHASONE

SUSPENSION/DROPS; OPHTHALMIC

DEXAMETHASONE

AT	STERIS	0.1%	N89170 001 MAY 09, 1989
	@	0.1%	N89170 001 MAY 09, 1989

MAXIDEX

AT	+ ALCON	0.1%	N13422 001
	+	0.1%	N13422 001

TABLET; ORAL

DEXONE 0.5

BP	SOLVAY	0.5MG	N84991 001
	@	0.5MG	N84991 001

DEXONE 0.75

BP	SOLVAY	0.75MG	N84993 001
	@	0.75MG	N84993 001

DEXONE 4

BP	SOLVAY	4MG	N84992 001
	@	4MG	N84992 001

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

MAXITROL

AT	+ ALCON	0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM		N50065 002
AT	+ FALCON PHARMS	0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM		N50065 002

SUSPENSION/DROPS; OPHTHALMIC

MAXITROL

AT	+ ALCON	0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML		N50023 002

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC

		MAXITROL		
AT	+	FALCON PHARMS	**0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML**	**N50023 002**

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

		DECADRON		
AP	+	MERCK	**EQ 24MG PHOSPHATE/ML**	**N12071 004**
	+		EQ 24MG PHOSPHATE/ML	N12071 004
		DEXAMETHASONE SODIUM PHOSPHATE		
AP		STERIS	**EQ 4MG PHOSPHATE/ML**	**N83702 001**
AP			**EQ 24MG PHOSPHATE/ML**	**N85606 001**
	@		EQ 4MG PHOSPHATE/ML	N83702 001
	@		EQ 24MG PHOSPHATE/ML	N85606 001

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

		DEXTROAMPHETAMINE SULFATE		
AA		ENDO PHARMS	**5MG**	**N40299 001**
				MAY 13, 1999

DEXTROSE

INJECTABLE; INJECTION

		DEXTROSE 25%		
>ADD<		ABBOTT	250MG/ML	N19445 002
>ADD<				NOV 23, 1998

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

		DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER		
AP		B BRAUN	**2.5GM/100ML;450MG/100ML**	**N18030 001**
	@		2.5GM/100ML;450MG/100ML	N18030 001
		DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER		
		B BRAUN	5GM/100ML;110MG/100ML	N18030 005
	@		5GM/100ML;110MG/100ML	N18030 005
		DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER		
AP		B BRAUN	**5GM/100ML;200MG/100ML**	**N18030 004**

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

		DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER		
	@	B BRAUN	5GM/100ML;200MG/100ML	N18030 004
		DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER		
AP		B BRAUN	**5GM/100ML;330MG/100ML**	**N18030 003**
	@		5GM/100ML;330MG/100ML	N18030 003
		DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER		
AP		B BRAUN	**5GM/100ML;450MG/100ML**	**N18030 002**
	@		5GM/100ML;450MG/100ML	N18030 002

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

		MD-76		
AP		MALLINCKRODT	**66%;10%**	**N87073 001**
	@		66%;10%	N87073 001

DIAZEPAM

GEL; RECTAL

		DIASTAT		
	+	ATHENA	2.5MG/0.5ML	N20648 001 JUL 29, 1997
			5MG/ML	N20648 002 JUL 29, 1997
			10MG/2ML	N20648 003 JUL 29, 1997
			15MG/3ML	N20648 004 JUL 29, 1997
	+		20MG/4ML	N20648 005 JUL 29, 1997
	+	ELAN PHARMS	2.5MG/0.5ML	N20648 001 JUL 29, 1997
			5MG/ML	N20648 002 JUL 29, 1997
			10MG/2ML	N20648 003 JUL 29, 1997
			15MG/3ML	N20648 004 JUL 29, 1997
	+		20MG/4ML	N20648 005 JUL 29, 1997

INJECTABLE; INJECTION

		DIAZEPAM		
AP		STERIS	**5MG/ML**	**N70911 001** AUG 28, 1986

DIAZEPAM

INJECTABLE; INJECTION

	DIAZEPAM			
AP	STERIS	5MG/ML	N70930 001	
			DEC 01, 1986	
	@	5MG/ML	N70911 001	
			AUG 28, 1986	
	@	5MG/ML	N70930 001	
			DEC 01, 1986	

DICLOFENAC POTASSIUM

TABLET; ORAL

	DICLOFENAC POTASSIUM		
AB	MYLAN	50MG	N75463 001
			JUL 26, 1999

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

	DICLOFENAC SODIUM		
AB	ALCON	0.1%	N20809 001
			MAY 04, 1998
AB	FALCON PHARMS	0.1% †	N20809 001
			MAY 04, 1998

TABLET, DELAYED RELEASE; ORAL

	DICLOFENAC SODIUM		
AB	MARTEC	50MG	N74986 001
			FEB 26, 1999
AB		75MG	N74986 002
			FEB 26, 1999
AB	NOVOPHARM	50MG	N74723 001
			MAR 30, 1999
AB	SIDMAK LABS NJ	50MG	N74432 002
			JUL 29, 1999
AB		75MG	N74432 003
			JUL 29, 1999

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

		DICYCLOMINE HCL		
>ADD<	AB	MYLAN	10MG	N40319 001
>ADD<				SEP 07, 1999

DICYCLOMINE HYDROCHLORIDE

TABLET; ORAL

		DICYCLOMINE HCL		
	AB	LANNETT	20MG	N40230 001
				FEB 26, 1999
>ADD<	AB	MYLAN	20MG	N40317 001
>ADD<				SEP 07, 1999

DIFLORASONE DIACETATE

CREAM; TOPICAL

	DIFLORASONE DIACETATE		
AB	TARO	0.05%	N75331 001
			MAY 14, 1999

OINTMENT; TOPICAL

	DIFLORASONE DIACETATE		
AB	ALTANA	0.05%	N75374 001
			APR 27, 1999
AB	TARO	0.05%	N75331 001
			MAY 14, 1999
	PSORCON		
AB +	PHARMACIA AND UPJOHN	0.05%	N19260 001
			AUG 28, 1985
+		0.05%	N19260 001
			AUG 28, 1985

DIFLUNISAL

TABLET; ORAL

	DIFLUNISAL		
AB	PUREPAC PHARM	250MG	N74285 001
			MAY 07, 1996
AB		500MG	N74285 002
			MAY 07, 1996
	@	250MG	N74285 001
			MAY 07, 1996
	@	500MG	N74285 002
			MAY 07, 1996

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

		CARDIZEM CD		
	AB3 +	CARDERM	120MG	N20062 001
				AUG 10, 1992

† SEE SECTION 1.3 OF INTRODUCTION

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDIZEM CD

AB3	+ CARDERM	180MG	N20062 002	
			DEC 27, 1991	
AB3	+	240MG	N20062 003	
			DEC 27, 1991	
AB3	+	300MG	N20062 004	
			DEC 27, 1991	
BC	+	120MG	N20062 001	
			AUG 10, 1992	
BC	+	180MG	N20062 002	
			DEC 27, 1991	
BC	+	240MG	N20062 003	
			DEC 27, 1991	
BC	+	300MG	N20062 004	
			DEC 27, 1991	

CARTIA XT

AB3	ANDRX PHARMS	120MG	N74752 002	
			JUL 09, 1998	
AB3		180MG	N74752 001	
			JUL 09, 1998	
AB3		240MG	N74752 003	
			JUL 09, 1998	
AB3		300MG	N74752 004	
			JUL 09, 1998	
	@	120MG	N74752 002	
			JUL 09, 1998	
	@	180MG	N74752 001	
			JUL 09, 1998	
	@	240MG	N74752 003	
			JUL 09, 1998	
	@	300MG	N74752 004	
			JUL 09, 1998	

DILTIAZEM HCL

> ADD > AB1	BIOVAIL	60MG	N74845 001	
> ADD >			SEP 15, 1999	
> ADD > AB1		90MG	N74845 002	
> ADD >			SEP 15, 1999	
> ADD > AB1		120MG	N74845 003	
> ADD >			SEP 15, 1999	

INJECTABLE; INJECTION

DILTIAZEM HCL

> ADD > AP	APOTEX	5MG/ML	N75375 001	
> ADD >			SEP 30, 1999	
AP	MERIDIAN MEDCL TECHN	5MG/ML	N75106 001	
			APR 29, 1999	

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HCL

> DLT > AA	PUREPAC PHARM	25MG	N85156 001	
> DLT > AA		50MG	N85150 001	
> ADD >	@	25MG	N85156 001	
> ADD >	@	50MG	N85150 001	

ELIXIR; ORAL

HYDRAMINE

AA	ALPHARMA	12.5MG/5ML	N80763 002	
	@	12.5MG/5ML	N80763 002	

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DIPIVEFRIN HCL

AT	ALCON	0.1%	N73636 001	
			JUN 30, 1994	
AT	FALCON PHARMS	0.1%	N73636 001	
			JUN 30, 1994	

DIPYRIDAMOLE

TABLET; ORAL

DIPYRIDAMOLE

AB	PUREPAC PHARM	25MG	N89425 001	
			JUL 12, 1990	
> DLT > AB		50MG	N89426 001	
> DLT >			JUL 12, 1990	
	@	25MG	N89425 001	
			JUL 12, 1990	
> ADD >	@	50MG	N89426 001	
> ADD >			JUL 12, 1990	

DIRITHROMYCIN

TABLET, DELAYED RELEASE; ORAL

DYNABAC

	+ LILLY	250MG	N50678 001	
			JUN 19, 1995	
	+ LILLY RES LABS	250MG	N50678 001	
			JUN 19, 1995	

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOPAMINE HCL

AP	SMITH AND NEPHEW	40MG/ML	N70046 001	AUG 29, 1985
AP		80MG/ML	N70047 001	AUG 29, 1985
	@	40MG/ML	N70046 001	AUG 29, 1985
	@	80MG/ML	N70047 001	AUG 29, 1985

DOXERCALCIFEROL

CAPSULE; ORAL
HECTOROL

+	BONE CARE	2.5 UGM	N20862 001	JUN 09, 1999

DOXORUBICIN HYDROCHLORIDE

INJECTABLE, LIPOSOMAL; INJECTION
DOXIL

+	ALZA	2MG/ML	N50718 001	NOV 17, 1995
+	SEQUUS	2MG/ML	N50718 001	NOV 17, 1995

DOXYCYCLINE HYCLATE

CAPSULE; ORAL
DOXYCYCLINE HYCLATE

> DLT >	@	PUREPAC PHARM	EQ 50MG BASE	N62479 001	DEC 23, 1983
> DLT >	@		EQ 100MG BASE	N62479 002	DEC 23, 1983
> ADD >	@	RANBAXY	EQ 50MG BASE	N62479 001	DEC 23, 1983
> ADD >	@		EQ 100MG BASE	N62479 002	DEC 23, 1983

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
BENDECTIN

@	HOECHST MARION RSSL	10MG;10MG	N10598 002

DROPERIDOL

INJECTABLE; INJECTION
DROPERIDOL

AP	SOLOPAK	2.5MG/ML	N71754 001	SEP 06, 1988
AP		2.5MG/ML	N71755 001	SEP 06, 1988
	@	2.5MG/ML	N71754 001	SEP 06, 1988
	@	2.5MG/ML	N71755 001	SEP 06, 1988
AP	STERIS	2.5MG/ML	N73520 001	NOV 27, 1991
AP		2.5MG/ML	N73521 001	NOV 27, 1991
AP		2.5MG/ML	N73523 001	NOV 27, 1991
	@	2.5MG/ML	N73520 001	NOV 27, 1991
	@	2.5MG/ML	N73521 001	NOV 27, 1991
	@	2.5MG/ML	N73523 001	NOV 27, 1991

ENALAPRIL MALEATE; FELODIPINE

TABLET, EXTENDED RELEASE; ORAL
LEXXEL

+	ASTRAZENECA	5MG;2.5MG	N20668 002	OCT 28, 1998

EPINEPHRINE

INJECTABLE; INJECTION
SUS-PHRINE

+	FOREST LABS	5MG/ML	N07942 001	

SUS-PHRINE SULFITE-FREE

	FOREST LABS	1.5MG/AMP	N07942 003	FEB 05, 1999

EPINEPHRINE

INJECTABLE; INJECTION
SUS-PHRINE SULFITE-FREE
+ FOREST LABS 5MG/ML N07942 001

> ADD > EPIRUBICIN HYDROCHLORIDE

> ADD > INJECTABLE; INJECTION
> ADD > ELLENCE
> ADD > + PHARMACIA AND UPJOHN 2MG/ML N50778 001
> ADD > SEP 15, 1999

EPROSARTAN MESYLATE

TABLET; ORAL
TEVETEN
> DLT > + SMITHKLINE BEECHAM EQ 400MG BASE N20738 005
> DLT > DEC 22, 1997
> ADD > EQ 400MG BASE N20738 005
> ADD > DEC 22, 1997
> ADD > + EQ 600MG BASE N20738 006
> ADD > MAY 27, 1999

ERGOTAMINE TARTRATE

AEROSOL, METERED; INHALATION
MEDIHALER ERGOTAMINE
+ 3M 0.36MG/INH N12102 001
@ 0.36MG/INH N12102 001

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL
ERYC
> DLT > @ PARKE DAVIS 250MG N62338 001
> ADD > @ WARNER CHILCOTT 250MG N62338 001

SOLUTION; TOPICAL
C-SOLVE-2
AT BIOGLAN PHAR 2% N62468 001
JUL 03, 1985
AT ZENITH GOLDLINE 2% N62468 001
JUL 03, 1985

> DLT > > DLT > BX + BERLEX LABS 0.025MG/24HR N20375 004
MAR 05, 1999

ESCLIM
> DLT > > DLT > BX FOURNIER 0.025MG/24HR N20847 001
AUG 04, 1998
> DLT > > DLT > BX 0.0375MG/24HR N20847 002
AUG 04, 1998
> DLT > > DLT > BX 0.05MG/24HR N20847 003
AUG 04, 1998
> DLT > > DLT > BX 0.075MG/24HR N20847 004
AUG 04, 1998
> DLT > > DLT > BX 0.1MG/24HR N20847 005
AUG 04, 1998
> ADD > > ADD > BX WOMEN FIRST HLTHCARE 0.025MG/24HR N20847 001
AUG 04, 1998
> ADD > > ADD > BX 0.0375MG/24HR N20847 002
AUG 04, 1998
> ADD > > ADD > BX 0.05MG/24HR N20847 003
AUG 04, 1998
> ADD > > ADD > BX 0.075MG/24HR N20847 004
AUG 04, 1998
> ADD > > ADD > BX 0.1MG/24HR N20847 005
AUG 04, 1998

ESTRADIOL
AB MENOREST 0.0375MG/24HR N20538 001
JUL 31, 1996
AB 0.05MG/24HR N20538 003
JUL 31, 1996
AB 0.075MG/24HR N20538 002
JUL 31, 1996
AB 0.1MG/24HR N20538 004
JUL 31, 1996
> ADD > > ADD > BX WYETH AYERST 0.05MG/24HR N21048 001
SEP 20, 1999
> ADD > > ADD > BX 0.075MG/24HR N21048 002
SEP 20, 1999
> ADD > > ADD > BX 0.1MG/24HR N21048 003
SEP 20, 1999

VIVELLE-DOT
AB NOVARTIS 0.0375MG/24HR N20538 001
JUL 31, 1996
AB 0.05MG/24HR N20538 003
JUL 31, 1996
AB 0.075MG/24HR N20538 002
JUL 31, 1996

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL
VIVELLE-DOT
AB NOVARTIS 0.1MG/24HR N20538 004 JUL 31, 1996

TABLET; ORAL
ESTRADIOL
AB MYLAN 0.5MG N40326 001 APR 21, 1999
AB 1MG N40326 002 APR 21, 1999
AB 2MG N40326 003 APR 21, 1999

TABLET; VAGINAL
VAGIFEM
\+ NOVO NORDISK 25 UGM N20908 001 MAR 26, 1999

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL
CENESTIN
DURAMED 0.9MG N20992 003 MAR 24, 1999
0.625MG N20992 002 MAR 24, 1999
\+ 0.9MG N20992 003 MAR 24, 1999

ESTRONE

INJECTABLE; INJECTION
NATURAL ESTROGENIC SUBSTANCE-ESTRONE
\+ STERIS 2MG/ML N85237 001 NOV 23, 1982
@ 2MG/ML N85237 001 NOV 23, 1982

ESTROPIPATE

CREAM; VAGINAL
OGEN
\+ ABBOTT 1.5MG/GM N84710 001

ESTROPIPATE

CREAM; VAGINAL
OGEN
\+ PHARMACIA AND UPJOHN 1.5MG/GM N84710 001

TABLET; ORAL
ESTROPIPATE
AB MYLAN 0.75MG N40359 001 AUG 26, 1999
AB 1.5MG N40359 002 AUG 26, 1999
AB 3MG N40359 003 AUG 26, 1999
OGEN .625
AB ABBOTT 0.75MG N83220 001
AB PHARMACIA AND UPJOHN 0.75MG N83220 001
OGEN 1.25
AB ABBOTT 1.5MG N83220 002
AB PHARMACIA AND UPJOHN 1.5MG N83220 002
OGEN 2.5
AB \+ ABBOTT 3MG N83220 003
AB \+ PHARMACIA AND UPJOHN 3MG N83220 003
OGEN 5
AB ABBOTT 6MG N83220 004
AB PHARMACIA AND UPJOHN 6MG N83220 004

ETHCHLORVYNOL

CAPSULE; ORAL
ETHCHLORVYNOL
>DLT> AA BANNER PHARMACAPS 200MG N84463 002
>DLT> AA 500MG N84463 003
>DLT> AA 750MG N84463 004
>DLT> 100MG N84463 001
>ADD> 100MG N84463 001
>ADD> @ 200MG N84463 002
>ADD> @ 500MG N84463 003
>ADD> @ 750MG N84463 004

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21
LEVLITE
BERLEX LABS 0.02MG;0.1MG N20860 001 JUL 13, 1998

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

	LEVLITE			
	+ BERLEX LABS	0.02MG;0.1MG	N20860 001	JUL 13, 1998

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

	BREVICON 21-DAY			
AB	SEARLE	0.035MG;0.5MG	N17566 001	
AB	WATSON LABS	0.035MG;0.5MG	N17566 001	
	NORINYL 1+35 21-DAY			
AB	SEARLE	0.035MG;1MG	N17565 001	
AB	WATSON LABS	0.035MG;1MG	N17565 001	
	TRI-NORINYL 21-DAY			
	+ SEARLE	0.035MG,0.035MG;0.5MG,1MG	N18977 001	APR 13, 1984
	+ WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N18977 001	APR 13, 1984

TABLET; ORAL-28

	BREVICON 28-DAY			
AB	SEARLE	0.035MG;0.5MG	N17743 001	
AB	WATSON LABS	0.035MG;0.5MG	N17743 001	
	NORINYL 1+35 28-DAY			
AB	SEARLE	0.035MG;1MG	N17565 002	
AB	WATSON LABS	0.035MG;1MG	N17565 002	
	TRI-NORINYL 28-DAY			
	SEARLE	0.035MG,0.035MG;0.5MG,1MG	N18977 002	APR 13, 1984
	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N18977 002	APR 13, 1984

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

	LO/OVRAL			
AB	+ WYETH AYERST	0.03MG;0.3MG	N17612 001	
	+	0.03MG;0.3MG	N17612 001	
	LOW-OGESTREL-21			
> DLT > AB	SCS	0.03MG;0.3MG	N75288 001	JUL 28, 1999
> DLT >				
> ADD > AB	WATSON LABS	0.03MG;0.3MG	N75288 001	JUL 28, 1999
> ADD >				

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-28

	LO/OVRAL-28			
AB	WYETH AYERST	0.03MG;0.3MG	N17802 001	
		0.03MG;0.3MG	N17802 001	
	LOW-OGESTREL-28			
> DLT > AB	SCS	0.03MG;0.3MG	N75288 002	JUL 28, 1999
> DLT >				
> ADD > AB	WATSON LABS	0.03MG;0.3MG	N75288 002	JUL 28, 1999
> ADD >				

ETODOLAC

CAPSULE; ORAL

	ETODOLAC			
> ADD > AB	NOVOPHARM NC	200MG	N75126 001	SEP 16, 1999
> ADD >				
> ADD > AB		300MG	N75126 002	SEP 16, 1999
> ADD >				

TABLET; ORAL

	ETODOLAC			
AB	EON	500MG	N74903 002	APR 19, 1999
AB	NOVOPHARM	400MG	N74847 001	APR 23, 1999
AB		500MG	N74847 002	APR 23, 1999

ETOPOSIDE

INJECTABLE; INJECTION

	ETOPOSIDE			
AP	AM PHARM PARTNERS	20MG/ML	N74983 001	SEP 30, 1998
AP	APPLIED ANAL	20MG/ML	N74983 001	SEP 30, 1998
AP	STERIS	20MG/ML	N74228 001	OCT 15, 1996
	@	20MG/ML	N74228 001	OCT 15, 1996
	VEPESID			
AP	+ BRISTOL	20MG/ML	N18768 001	NOV 10, 1983
AP	+ BRISTOL MYERS SQUIBB	20MG/ML	N18768 001	NOV 10, 1983

ETRETINATE

CAPSULE; ORAL

>DLT>		TEGISON		
>DLT>		ROCHE	10MG	N19369 001 SEP 30, 1986
>DLT>	+		25MG	N19369 002 SEP 30, 1986
>DLT>	@		10MG	N19369 001 SEP 30, 1986
>ADD>	@		25MG	N19369 002 SEP 30, 1986

FERRIC SODIUM GLUCONATE

INJECTABLE; INJECTION

		FERRLECIT		
	+	R AND D LABS	62.5MG/5ML	N20955 001 FEB 18, 1999

FLUOCINONIDE

OINTMENT; TOPICAL

		FLUOCINONIDE		
AB		TARO	0.05%	N75008 001 JUN 30, 1999

FLUOROURACIL

INJECTABLE; INJECTION

		FLUOROURACIL		
AP		BIGMAR	50MG/ML	N40291 001 MAR 24, 1999
AP		SMITH AND NEPHEW	50MG/ML	N88767 001 DEC 28, 1984
AP			50MG/ML	N89434 001 MAR 26, 1987
	@		50MG/ML	N88767 001 DEC 28, 1984
	@		50MG/ML	N89434 001 MAR 26, 1987

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

		PROZAC		
	+	LILLY	EQ 20MG BASE	N18936 001 DEC 29, 1987
			EQ 20MG BASE	N18936 001 DEC 29, 1987
	+		EQ 40MG BASE	N18936 003 JUN 15, 1999
	@		EQ 60MG BASE	N18936 004 JUN 15, 1999

TABLET; ORAL

		PROZAC		
		LILLY	EQ 10MG BASE	N20974 001 MAR 09, 1999
	+		EQ 20MG BASE	N20974 002 MAR 09, 1999
	+		EQ 10MG BASE	N20974 001 MAR 09, 1999
	@		EQ 20MG BASE	N20974 002 MAR 09, 1999

FOLIC ACID

TABLET; ORAL

		FOLIC ACID		
>DLT>	AA	VINTAGE PHARMS	1MG	N86296 001
>ADD>	@		1MG	N86296 001

FUROSEMIDE

INJECTABLE; INJECTION

		FUROSEMIDE		
AP		ABBOTT	10MG/ML	N75241 001 MAY 28, 1999
AP		SMITH AND NEPHEW	10MG/ML	N70078 001 FEB 05, 1986
	@		10MG/ML	N70078 001 FEB 05, 1986
AP		STERIS	10MG/ML	N70019 001 SEP 22, 1986
AP			10MG/ML	N70604 001 JAN 02, 1987
	@		10MG/ML	N70019 001 SEP 22, 1986

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE
@ STERIS — 10MG/ML — N70604 001 — JAN 02, 1987

GALLAMINE TRIETHIODIDE

INJECTABLE; INJECTION
FLAXEDIL
+ DAVIS AND GECK — 20MG/ML — N07842 001
+ — 100MG/ML — N07842 002
@ — 20MG/ML — N07842 001
@ — 100MG/ML — N07842 002

GALLIUM NITRATE

INJECTABLE; INJECTION
GANITE
+ SOLOPAK — 25MG/ML — N19961 002 — JAN 17, 1991
@ — 25MG/ML — N19961 002 — JAN 17, 1991

GANIRELIX ACETATE

INJECTABLE; INJECTION
ANTAGON
+ ORGANON INC — EQ 250 UGM BASE/0.5ML — N21057 001 — JUL 29, 1999

GEMFIBROZIL

TABLET; ORAL
GEMFIBROZIL
> DLT > **AB** PUREPAC PHARM — **600MG** — **N74360 001** — AUG 31, 1994
> DLT >
> ADD > @ — 600MG — N74360 001 — AUG 31, 1994
> ADD >

GENTAMICIN SULFATE

INJECTABLE; INJECTION
> DLT > **APOGEN**
> DLT > **AP** KING PHARMS — **EQ 10MG BASE/ML** — **N62289 001**
> DLT > **AP** — **EQ 40MG BASE/ML** — **N62289 002**
> ADD > @ — EQ 10MG BASE/ML — N62289 001
> ADD > @ — EQ 40MG BASE/ML — N62289 002
> DLT > **BRISTAGEN**
> DLT > **AP** BRISTOL — **EQ 40MG BASE/ML** — **N62288 001**
> ADD > @ — EQ 40MG BASE/ML — N62288 001
GENTAMICIN SULFATE
AP SOLOPAK — **EQ 10MG BASE/ML** — **N62507 001** — JUN 06, 1985
AP — **EQ 40MG BASE/ML** — **N62507 002** — JUN 06, 1985
@ — EQ 10MG BASE/ML — N62507 001 — JUN 06, 1985
@ — EQ 40MG BASE/ML — N62507 002 — JUN 06, 1985

SOLUTION/DROPS; OPHTHALMIC
GENTAMICIN SULFATE
AT ALCON — **EQ 0.3% BASE** — **N62196 001**
AT FALCON PHARMS — **EQ 0.3% BASE** — **N62196 001**

GLIPIZIDE

TABLET; ORAL
GLUCOTROL
PFIZER — 2.5MG — N17783 003 — MAY 11, 1993
@ — 2.5MG — N17783 003 — MAY 11, 1993

TABLET, EXTENDED RELEASE; ORAL
GLUCOTROL XL
> ADD > + PFIZER — 2.5MG — N20329 003 — AUG 10, 1999
> ADD >

GLYBURIDE

TABLET; ORAL
GLYBURIDE (MICRONIZED)
AB MOVA — **4.5MG** — **N74591 003** — DEC 22, 1997

GLYBURIDE

TABLET; ORAL

	GLYBURIDE (MICRONIZED)		
	MOVA	4.5MG	N74591 003 DEC 22, 1997
AB	MYLAN	6MG	N74792 003 AUG 17, 1999
AB	NOVOPHARM	1.5MG	N74686 001 APR 20, 1999
AB		3MG	N74686 002 APR 20, 1999
AB		4.5MG	N74686 003 APR 20, 1999
AB		6MG	N74686 004 APR 20, 1999

GLYCOPYRROLATE

INJECTABLE; INJECTION

	GLYCOPYRROLATE		
AP	STERIS	0.2MG/ML	N86947 001 JUN 24, 1983
@		0.2MG/ML	N86947 001 JUN 24, 1983

TABLET; ORAL

	ROBINUL		
+	HORIZON PHARM	1MG	N12827 001
+	ROBINS AH	1MG	N12827 001
	ROBINUL FORTE		
+	HORIZON PHARM	2MG	N12827 002
+	ROBINS AH	2MG	N12827 002

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

	NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN		
AT	STERIS	0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N62788 001 JUN 11, 1987
@		0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N62788 001 JUN 11, 1987

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

	HALOPERIDOL DECANOATE		
AO	GENSIA SICOR PHARMS	EQ 50MG BASE/ML	N75393 001 MAY 11, 1999
AO		EQ 100MG BASE/ML	N75393 002 MAY 11, 1999

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

	HALOPERIDOL		
AP	SOLOPAK	EQ 5MG BASE/ML	N70801 001 DEC 14, 1987
AP		EQ 5MG BASE/ML	N70864 001 DEC 14, 1987
@		EQ 5MG BASE/ML	N70801 001 DEC 14, 1987
@		EQ 5MG BASE/ML	N70864 001 DEC 14, 1987
AP	STERIS	EQ 5MG BASE/ML	N70713 001 MAY 17, 1988
AP		EQ 5MG BASE/ML	N70744 001 MAY 17, 1988
@		EQ 5MG BASE/ML	N70713 001 MAY 17, 1988
@		EQ 5MG BASE/ML	N70744 001 MAY 17, 1988

HEPARIN SODIUM

INJECTABLE; INJECTION

	HEPARIN LOCK FLUSH		
AP	SMITH AND NEPHEW	10 UNITS/ML	N88458 001 JUL 26, 1984
AP		10 UNITS/ML	N88580 001 OCT 25, 1984
AP		100 UNITS/ML	N88460 001 JUL 26, 1984
AP		100 UNITS/ML	N88581 001 OCT 25, 1984
@		10 UNITS/ML	N88458 001 JUL 26, 1984
@		10 UNITS/ML	N88580 001 OCT 25, 1984

HEPARIN SODIUM

INJECTABLE; INJECTION

	HEPARIN LOCK FLUSH			
	@ SMITH AND NEPHEW	100 UNITS/ML	N88460 001	JUL 26, 1984
	@	100 UNITS/ML	N88581 001	OCT 25, 1984
AP	SOLOPAK	**100 UNITS/ML**	**N88459 001**	JUL 26, 1984
	@	100 UNITS/ML	N88459 001	JUL 26, 1984
	HEPARIN SODIUM			
AP	SMITH AND NEPHEW	**1,000 UNITS/ML**	**N88239 001**	JUL 26, 1984
	@	1,000 UNITS/ML	N88239 001	JUL 26, 1984

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

	HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE			
AA	HALSEY	**1.5MG/5ML;5MG/5ML**	**N40285 001**	JUL 19, 1999

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

	HYDRALAZINE HCL			
AP	+ LUITPOLD	**20MG/ML**	**N40136 001**	JUN 30, 1997
	+	20MG/ML	N40136 001	JUN 30, 1997
AP	SOLOPAK	**20MG/ML**	**N88517 001**	AUG 22, 1985
	@	20MG/ML	N88517 001	AUG 22, 1985

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

	HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE			
AB	SOLVAY	**25MG;25MG**	**N87608 001**	FEB 08, 1982
AB		**50MG;50MG**	**N87213 001**	FEB 08, 1982

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

	HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE			
	@ SOLVAY	25MG;25MG	N87608 001	FEB 08, 1982
	@	50MG;50MG	N87213 001	FEB 08, 1982

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

	RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE			
BP	SOLVAY	25MG;15MG;0.1MG	N88376 001	OCT 28, 1983
	@	25MG;15MG;0.1MG	N88376 001	OCT 28, 1983

HYDROCHLOROTHIAZIDE

TABLET; ORAL

		HYDROCHLOROTHIAZIDE			
> DLT >	**AB**	MAST MM	**25MG**	**N86192 001**	
> DLT >	**AB**		**50MG**	**N86192 002**	
> ADD >		@	25MG	N86192 001	
> ADD >		@	50MG	N86192 002	

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

	AVALIDE			
	@ SANOFI SYNTHELABO	12.5MG;75MG	N20758 001	SEP 30, 1997
		12.5MG;150MG	N20758 002	SEP 30, 1997
	+	12.5MG;300MG	N20758 003	AUG 31, 1998
	AVAPRO HCT			
	@ SANOFI	12.5MG;75MG	N20758 001	SEP 30, 1997
	+	12.5MG;150MG	N20758 002	SEP 30, 1997

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB		DURAMED	25MG;37.5MG	N75052 001 JUN 18, 1999

HYDROCORTISONE

CREAM; TOPICAL
HYDROCORTISONE

> DLT >	AT		G AND W LABS	1%	N84059 001
> ADD >		@		1%	N84059 001

ENEMA; RECTAL
CORTENEMA

AB	+		SOLVAY	100MG/60ML	N16199 001
BR	+			100MG/60ML	N16199 001

HYDROCORTISONE

AB			COPLEY PHARM	100MG/60ML	N74171 001 MAY 27, 1994
BR				100MG/60ML	N74171 001 MAY 27, 1994

LOTION; TOPICAL
DERMACORT

AT			SOLVAY	0.5%	N84573 002
AT				1%	N86462 001
	@			0.5%	N84573 002
	@			1%	N86462 001

HYDROCORTISONE

AT			THAMES	2.5%	N40247 001 JUL 23, 1999

SOLUTION; TOPICAL
TEXACORT

> ADD >	AT	+	BIOGLAN PHAR	1%	N80425 001
> ADD >		+		2.5%	N81271 001 APR 17, 1992
> DLT >		+	GENDERM	2.5%	N81271 001 APR 17, 1992
> DLT >	AT	+	MEDICIS	1%	N80425 001

HYDROCORTISONE ACETATE

CREAM; TOPICAL
HYDROCORTISONE ACETATE

+	FERNDALE LABS	2.5%	N40259 001 JUL 29, 1999

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION
HYDROCORTISONE SODIUM SUCCINATE

AP	STERIS	EQ 100MG BASE/VIAL	N84737 002
AP		EQ 100MG BASE/VIAL	N84738 001
AP		EQ 250MG BASE/VIAL	N84737 001
AP		EQ 500MG BASE/VIAL	N84747 001
AP		EQ 1GM BASE/VIAL	N84748 001
@		EQ 100MG BASE/VIAL	N84737 002
@		EQ 100MG BASE/VIAL	N84738 001
@		EQ 250MG BASE/VIAL	N84737 001
@		EQ 500MG BASE/VIAL	N84747 001
@		EQ 1GM BASE/VIAL	N84748 001

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS; OPHTHALMIC
PAREDRINE

+	AKORN	1%	N00004 004
+	PHARMICS	1%	N00004 004

HYDROXYUREA

CAPSULE; ORAL
HYDROXYUREA

AB	PAR PHARM	500MG	N75340 001 FEB 24, 1999

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDROXYZINE HCL

AP	SOLOPAK	25MG/ML	N87591 001
AP		50MG/ML	N87593 001
AP		50MG/ML	N87595 001
@		25MG/ML	N87591 001
@		50MG/ML	N87593 001

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDROXYZINE HCL
@ SOLOPAK 50MG/ML N87595 001

IBUPROFEN

SUSPENSION; ORAL
MOTRIN
AB + MCNEIL 100MG/5ML N19842 001 SEP 19, 1989
AB + MCNEIL CONS 100MG/5ML N19842 001 SEP 19, 1989

TABLET; ORAL
IBUPROFEN
AB NORTON HN 400MG N71145 001 SEP 23, 1986
AB 600MG N71146 001 SEP 23, 1986
AB 800MG N71769 001 MAY 08, 1987
AB ZENITH GOLDLINE 400MG N71145 001 SEP 23, 1986
AB 600MG N71146 001 SEP 23, 1986
AB 800MG N71769 001 MAY 08, 1987

MOTRIN
AB MCNEIL 300MG N17463 003
AB 400MG N17463 002
AB 600MG N17463 004
AB + 800MG N17463 005 MAY 22, 1985
100MG N20418 001 NOV 16, 1994
AB MCNEIL CONS 300MG N17463 003
AB 400MG N17463 002
AB 600MG N17463 004
AB + 800MG N17463 005 MAY 22, 1985
100MG N20418 001 NOV 16, 1994

TABLET, CHEWABLE; ORAL
MOTRIN
MCNEIL 50MG N20135 001 NOV 16, 1994

IBUPROFEN

TABLET, CHEWABLE; ORAL
MOTRIN
+ MCNEIL 100MG N20135 002 NOV 16, 1994
MCNEIL CONS 50MG N20135 001 NOV 16, 1994
+ 100MG N20135 002 NOV 16, 1994

IMIGLUCERASE

INJECTABLE; INJECTION
CEREZYME
> DLT > **+ GENZYME 200 UNITS/VIAL N20367 001 MAY 23, 1994**
> DLT > > ADD > 200 UNITS/VIAL N20367 001 MAY 23, 1994
> ADD > > ADD > + 400 UNITS/VIAL N20367 002 SEP 22, 1999

INDOMETHACIN

CAPSULE, EXTENDED RELEASE; ORAL
INDOCIN SR
AB EON 75MG N74464 001 MAY 28, 1998
AB + MERCK 75MG N18185 001 FEB 23, 1982
@ 75MG N18185 001 FEB 23, 1982

INDOMETHACIN
AB EON LABS MFG 75MG N74464 001 MAY 28, 1998

INSULIN HUMAN

INJECTABLE; INJECTION
VELOSULIN BR
+ NOVO NORDISK 100 UNITS/ML N21028 001 JUL 19, 1999

IPRATROPIUM BROMIDE

SOLUTION; INHALATION
IPRATROPIUM BROMIDE

AN		ALPHARMA	0.02%	N75111 001 APR 22, 1999

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION
ISOETHARINE HCL

AN		INTL MEDICATION	0.08%	N86651 002
AN			0.1%	N86651 003
AN	+		0.1%	N86651 003
AN			0.167%	N86651 005
AN	+		0.167%	N86651 005
AN			0.25%	N86651 007
AN	+		0.25%	N86651 007
	+		0.08%	N86651 002

ISOETHARINE HCL S/F

AN	+	DEY	0.08%	N89817 001 NOV 22, 1988
AN	+		0.1%	N89818 001 NOV 22, 1988
AN	+		0.17%	N89819 001 NOV 22, 1988
AN	+		0.25%	N89820 001 NOV 22, 1988
	@		0.08%	N89817 001 NOV 22, 1988
	@		0.1%	N89818 001 NOV 22, 1988
	@		0.17%	N89819 001 NOV 22, 1988
	@		0.25%	N89820 001 NOV 22, 1988

ISOFLURANE

LIQUID; INHALATION
FORANE

AN	+	BAXTER PHARM PROD	99.9%	N17624 001
AN	+	OHMEDA	99.9%	N17624 001

ISONIAZID; RIFAMPIN

CAPSULE; ORAL
RIFAMATE

	+	DOW PHARM	150MG;300MG	N61884 001
	+	HOECHST MARION RSSL	150MG;300MG	N61884 001

ISOSORBIDE DINITRATE

TABLET; ORAL
SORBITRATE

AB		ZENECA	30MG	N88124 001 AUG 21, 1990
	@		30MG	N88124 001 AUG 21, 1990

ISOTRETINOIN

CAPSULE; ORAL
ACCUTANE

		HLR	10MG	N18662 002 MAY 07, 1982
			20MG	N18662 004 MAR 28, 1983
	+		40MG	N18662 003 MAY 07, 1982
		ROCHE	10MG	N18662 002 MAY 07, 1982
			20MG	N18662 004 MAR 28, 1983
	+		40MG	N18662 003 MAY 07, 1982

ITRACONAZOLE

INJECTABLE; INJECTION
SPORANOX

	+	JANSSEN	10MG/ML	N20966 001 MAR 30, 1999

KANAMYCIN SULFATE

INJECTABLE; INJECTION
KANAMYCIN SULFATE

AP		SOLOPAK	EQ 75MG BASE/2ML	N62605 003 FEB 26, 1986

KANAMYCIN SULFATE

INJECTABLE; INJECTION
KANAMYCIN SULFATE

AP	SOLOPAK	**EQ 500MG BASE/2ML**	**N62605 001** FEB 26, 1986
AP		**EQ 1GM BASE/3ML**	**N62605 002** FEB 26, 1986
@		EQ 75MG BASE/2ML	N62605 003 FEB 26, 1986
@		EQ 500MG BASE/2ML	N62605 001 FEB 26, 1986
@		EQ 1GM BASE/3ML	N62605 002 FEB 26, 1986

KETOCONAZOLE

TABLET; ORAL
KETOCONAZOLE

AB	APPLIED ANAL	**200MG**	**N75341 001** JUL 27, 1999
AB	MUTUAL PHARMA	**200MG**	**N75314 001** JUN 15, 1999
AB	NOVOPHARM	**200MG**	**N74971 001** JUN 15, 1999
AB	SIDMAK LABS CA	**200MG**	**N75362 001** JUN 15, 1999
AB	TARO	**200MG**	**N75319 001** JUN 15, 1999
AB	TEVA	**200MG**	**N75273 001** JUN 15, 1999

NIZORAL

AB +	JANSSEN	**200MG**	**N18533 001**
+		200MG	N18533 001

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL
KETOPROFEN

AB	ANDRX PHARMS	**100MG**	**N75270 002** MAR 24, 1999
AB		**150MG**	**N75270 003** MAR 24, 1999
AB		**200MG**	**N75270 001** MAR 24, 1999

ORUVAIL

AB	WYETH AYERST	**100MG**	**N19816 003** FEB 08, 1995

> ADD >
> ADD >

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL
ORUVAIL

AB	WYETH AYERST	**150MG**	**N19816 002** FEB 08, 1995
		100MG	N19816 003 FEB 08, 1995
		150MG	N19816 002 FEB 08, 1995

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION
KETOROLAC TROMETHAMINE

AP	ABBOTT	**15MG/ML**	**N74993 001** JAN 27, 1999
AP		**30MG/ML**	**N74993 002** JAN 27, 1999
AP	BEDFORD	**15MG/ML**	**N75222 001** APR 26, 1999
AP		**30MG/ML**	**N75222 002** APR 26, 1999
AP		**30MG/ML**	**N75228 001** APR 26, 1999

TABLET; ORAL
KETOROLAC TROMETHAMINE

AB	SIDMAK LABS CA	**10MG**	**N75284 001** JUN 23, 1999

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC
ZADITOR

+	CIBA	EQ 0.025% BASE	N21066 001 JUL 02, 1999

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION
LABETALOL HCL

AP	BEDFORD	**5MG/ML**	**N75303 001** MAY 28, 1999
AP	FAULDING	**5MG/ML**	**N75242 001** SEP 30, 1999

LABETALOL HYDROCHLORIDE

TABLET; ORAL

LABETALOL HCL

AB	MUTUAL PHARM	**100MG**	**N75215 001** JUL 29, 1999
AB		**200MG**	**N75215 002** JUL 29, 1999
AB		**300MG**	**N75215 003** JUL 29, 1999

TRANDATE

AB	FARO PHARMS	**100MG**	**N18716 001** MAY 24, 1985
AB		**200MG**	**N18716 002** AUG 01, 1984
AB		**300MG**	**N18716 003** AUG 01, 1984
@		400MG	N18716 004 AUG 01, 1984
AB	GLAXO WELLCOME	**100MG**	**N18716 001** MAY 24, 1985
AB		**200MG**	**N18716 002** AUG 01, 1984
AB		**300MG**	**N18716 003** AUG 01, 1984
@		400MG	N18716 004 AUG 01, 1984

LACTULOSE

SOLUTION; ORAL

LACTULOSE

AA	PACO	**10GM/15ML**	**N73160 001** AUG 25, 1992
@		10GM/15ML	N73160 001 AUG 25, 1992

SOLUTION; ORAL, RECTAL

LACTULOSE

AA	PACO	**10GM/15ML**	**N72029 001** AUG 25, 1992
@		10GM/15ML	N72029 001 AUG 25, 1992

LAMIVUDINE

SOLUTION; ORAL

EPIVIR-HBV

+	GLAXO WELLCOME	5MG/ML	N20596 002 DEC 08, 1998
		5MG/ML	N20596 002 DEC 08, 1998
+		5MG/ML	N21004 001 DEC 08, 1998

TABLET; ORAL

EPIVIR-HBV

+	GLAXO WELLCOME	100MG	N20564 002 DEC 08, 1998
		100MG	N20564 002 DEC 08, 1998
+		100MG	N21003 001 DEC 08, 1998

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

AP	+ ABBOTT	**EQ 10MG BASE/ML**	**N40147 001** JUN 25, 1997
AP	+ BEDFORD	**EQ 200MG BASE/VIAL**	**N40056 001** MAY 23, 1995

LEUCOVORIN CALCIUM PRESERVATIVE FREE

	+ ABBOTT	EQ 10MG BASE/ML	N40147 001 JUN 25, 1997
AP	+ BEDFORD	**EQ 200MG BASE/VIAL**	**N40056 001** MAY 23, 1995
AP	BIGMAR	**EQ 10MG BASE/ML**	**N40286 001** FEB 26, 1999
AP		**EQ 200MG BASE/VIAL**	**N40258 001** FEB 26, 1999
	+	EQ 500MG BASE/VIAL	N40286 001 FEB 26, 1999
AP	GENSIA SICOR PHARMS	**EQ 10MG BASE/ML**	**N40332 001** JUN 28, 1999

TABLET; ORAL

LEUCOVORIN CALCIUM

AB	INVAMED	**EQ 15MG BASE**	**N75327 001** MAR 24, 1999

WELLCOVORIN

AB	GLAXO WELLCOME	**EQ 5MG BASE**	**N18342 001** JUL 08, 1983

LEUCOVORIN CALCIUM

TABLET; ORAL
WELLCOVORIN
AB + GLAXO WELLCOME EQ 25MG BASE N18342 002 JUL 08, 1983
@ EQ 5MG BASE N18342 001 JUL 08, 1983
@ EQ 25MG BASE N18342 002 JUL 08, 1983

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION
XOPENEX
+ SEPRACOR EQ 0.021% BASE N20837 001 MAR 25, 1999
+ EQ 0.042% BASE N20837 002 MAR 25, 1999

LEVOBUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
CHIROCAINE
DARWIN DISCOVERY EQ 2.5MG BASE/ML N20997 001 AUG 05, 1999
EQ 5MG BASE/ML N20997 002 AUG 05, 1999
+ EQ 7.5MG BASE/ML N20997 003 AUG 05, 1999

LEVONORGESTREL

TABLET; ORAL
PLAN B
+ WOMENS CAPITAL 0.75MG N21045 001 JUL 28, 1999

LIDOCAINE

FILM, EXTENDED RELEASE; TOPICAL
LIDODERM
+ TEIKOKU PHARMA USA 700MG/12HR N20612 001 MAR 19, 1999

LIDOCAINE

FILM, EXTENDED RELEASE; TRANSDERMAL
LIDODERM
+ HIND HLTHCARE 700MG/12HR N20612 001 MAR 19, 1999

LIDOCAINE; PRILOCAINE

AEROSOL; TOPICAL
EMLA
+ ASTRA PHARMS 2.5%;2.5% N20962 001 FEB 04, 1998

DISC; TOPICAL
EMLA
+ ASTRAZENECA 2.5%;2.5% N20962 001 FEB 04, 1998

LISINOPRIL

TABLET; ORAL
ZESTRIL
ZENECA 30MG N19777 006 JAN 20, 1999

LITHIUM CARBONATE

CAPSULE; ORAL
LITHONATE
AB SOLVAY 300MG N16782 001
@ 300MG N16782 001

TABLET; ORAL
LITHIUM CARBONATE
AB PFIZER 300MG N16834 001
AB + 300MG N16834 001
LITHOTABS
AB + SOLVAY 300MG N16980 001
@ 300MG N16980 001

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL
IMODIUM
AB + JANSSEN 2MG N17694 001

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL

	IMODIUM			
	@ JANSSEN	2MG		N17690 001
AB	+ MCNEIL CONS	2MG		N17694 001
	@	2MG		N17690 001

LORACARBEF

CAPSULE; ORAL

LORABID			
KING PHARMS	200MG		N50668 001 DEC 31, 1991
+	400MG		N50668 002 APR 05, 1996
LILLY	200MG		N50668 001 DEC 31, 1991
+	400MG		N50668 002 APR 05, 1996

POWDER FOR RECONSTITUTION; ORAL

LORABID			
KING PHARMS	100MG/5ML		N50667 001 DEC 31, 1991
+	200MG/5ML		N50667 002 DEC 31, 1991
LILLY	100MG/5ML		N50667 001 DEC 31, 1991
+	200MG/5ML		N50667 002 DEC 31, 1991

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS; OPHTHALMIC

LOTEMAX			
+ PHARMOS	0.5%		N20841 001 MAR 09, 1998
@	0.5%		N20841 001 MAR 09, 1998

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION

ISOLYTE S PH 7.4 IN PLASTIC CONTAINER			
B BRAUN	30MG/100ML;37MG/100ML;0.82MG/100ML; 370MG/100ML;530MG/100ML;500MG/100ML; 12MG/100ML		N19006 001 APR 04, 1984
@	30MG/100ML;37MG/100ML;0.82MG/100ML; 370MG/100ML;530MG/100ML;500MG/100ML; 12MG/100ML		N19006 001 APR 04, 1984

MALATHION

LOTION; TOPICAL

OVIDE			
@ MEDICIS	0.5%		N18613 001 AUG 02, 1982
+	0.5%		N18613 001 AUG 02, 1982

MANNITOL

INJECTABLE; INJECTION

	MANNITOL 25%			
AP	STERIS	12.5GM/50ML		N87460 001 JUN 27, 1983
	@	12.5GM/50ML		N87460 001 JUN 27, 1983

MEBENDAZOLE

TABLET, CHEWABLE; ORAL

	VERMOX			
AB	+ JANSSEN	100MG		N17481 001
AB	+ MCNEIL CONS	100MG		N17481 001

MECLOCYCLINE SULFOSALICYLATE

CREAM; TOPICAL

MECLAN			
+ JOHNSON AND JOHNSON	1%		N50518 001

MECLOCYCLINE SULFOSALICYLATE

CREAM; TOPICAL
MECLAN
@ JOHNSON AND JOHNSON 1% N50518 001

MEDROXYPROGESTERONE ACETATE

TABLET; ORAL
CYCRIN
ESI 2.5MG N81239 001 OCT 30, 1992
5MG N81240 001 OCT 30, 1992
10MG N89386 001 SEP 09, 1987
@ 2.5MG N81239 001 OCT 30, 1992
@ 5MG N81240 001 OCT 30, 1992
@ 10MG N89386 001 SEP 09, 1987

MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION
REPRONEX
BX FERRING 75 IU/VIAL;75 IU/VIAL N21047 001 AUG 27, 1999
BX 150 IU/VIAL;150 IU/VIAL N21047 002 AUG 27, 1999

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
DEMEROL
> DLT > **AP** + ABBOTT **25MG/ML** **N05010 007**
> DLT > **AP** + **50MG/ML** **N05010 002**
> DLT > **AP** + **75MG/ML** **N05010 009**
> DLT > **AP** + **100MG/ML** **N05010 003**
> ADD > **AP** + SANOFI SYNTHELABO **25MG/ML** **N05010 007**
> ADD > **AP** + **50MG/ML** **N05010 002**
> ADD > **AP** + **75MG/ML** **N05010 009**
> ADD > **AP** + **100MG/ML** **N05010 003**
MEPERIDINE HCL
AP + ABBOTT **10MG/ML** **N88432 001** AUG 16, 1984

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
MEPERIDINE HCL
AP ASTRA PHARMS **10MG/ML** **N81002 001** JUL 30, 1993
AP INTL MEDICATION **10MG/ML** **N81309 001** AUG 30, 1993
AP MALLINCKRODT **10MG/ML** **N40163 001** MAY 12, 1997
AP STERIS **10MG/ML** **N73443 001** MAR 17, 1992

MEPERIDINE HCL PRESERVATIVE FREE
AP + ABBOTT **10MG/ML** **N88432 001** AUG 16, 1984
AP ASTRA PHARMS **10MG/ML** **N81002 001** JUL 30, 1993
AP FAULDING **10MG/ML** **N40305 001** MAR 10, 1999
AP INTL MEDICATION **10MG/ML** **N81309 001** AUG 30, 1993
AP MALLINCKRODT **10MG/ML** **N40163 001** MAY 12, 1997
AP STERIS **10MG/ML** **N73443 001** MAR 17, 1992

SYRUP; ORAL
DEMEROL
> DLT > **AA** + ABBOTT **50MG/5ML** **N05010 005**
> ADD > **AA** + SANOFI SYNTHELABO **50MG/5ML** **N05010 005**

TABLET; ORAL
DEMEROL
> DLT > **AA** + ABBOTT **50MG** **N05010 001**
> DLT > **AA** + **100MG** **N05010 004**
> ADD > **AA** + SANOFI SYNTHELABO **50MG** **N05010 001**
> ADD > **AA** + **100MG** **N05010 004**
MEPERIDINE HCL
AA AMIDE PHARM **50MG** **N40331 001** MAY 28, 1999
AA **100MG** **N40331 002** MAY 28, 1999

MEPROBAMATE

TABLET; ORAL
MEPROBAMATE
> DLT > **AA** PHARMAVITE **400MG** **N84438 001**

MEPROBAMATE

TABLET; ORAL
MEPROBAMATE

> ADD >	@ PHARMAVITE	400MG		N84438 001

MERSALYL SODIUM; THEOPHYLLINE

INJECTABLE; INJECTION
MERSALYL-THEOPHYLLINE

+	STERIS	100MG/ML;50MG/ML	N84875 001
@		100MG/ML;50MG/ML	N84875 001

METFORMIN HYDROCHLORIDE

TABLET; ORAL
GLUCOPHAGE

+	BRISTOL MYERS SQUIBB	500MG	N20357 001 MAR 03, 1995
		625MG	N20357 003 NOV 05, 1998
		750MG	N20357 004 NOV 05, 1998
		500MG	N20357 001 MAR 03, 1995
@		625MG	N20357 003 NOV 05, 1998
@		750MG	N20357 004 NOV 05, 1998

METHOTREXATE SODIUM

INJECTABLE; INJECTION
METHOTREXATE

AP	BIGMAR	EQ 25MG BASE/ML	N40263 001 FEB 26, 1999

METHOTREXATE PRESERVATIVE FREE

AP	BIGMAR	EQ 25MG BASE/ML	N40265 001 FEB 26, 1999
AP		EQ 1GM BASE/VIAL	N40266 001 FEB 26, 1999

METHOTREXATE SODIUM

+	LEDERLE	EQ 1GM BASE/VIAL	N11719 009 APR 07, 1988

METHOTREXATE SODIUM PRESERVATIVE FREE

AP	+ LEDERLE	EQ 1GM BASE/VIAL	N11719 009 APR 07, 1988

METHOTREXATE SODIUM

TABLET; ORAL
METHOTREXATE SODIUM

AB	DURAMED	EQ 2.5MG BASE		N40233 001 JUN 17, 1999

METHOTRIMEPRAZINE

INJECTABLE; INJECTION
LEVOPROME

+	IMMUNEX	20MG/ML	N15865 001
@		20MG/ML	N15865 001

METHOXSALEN

INJECTABLE; INJECTION
UVADEX

+	THERAKOS	0.02MG/ML	N20969 001 FEB 25, 1999

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION
METHYLDOPATE HCL

AP	SMITH AND NEPHEW	50MG/ML	N70841 001 JAN 02, 1987
@		50MG/ML	N70841 001 JAN 02, 1987

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION
METHYLPREDNISOLONE SODIUM SUCCINATE

AP	STERIS	EQ 40MG BASE/VIAL	N86953 001 JUL 22, 1982
AP		EQ 125MG BASE/VIAL	N87030 001 JUL 22, 1982
AP		EQ 500MG BASE/VIAL	N88523 001 JUL 24, 1984
AP		EQ 1GM BASE/VIAL	N88524 001 JUL 24, 1984
@		EQ 40MG BASE/VIAL	N86953 001 JUL 22, 1982

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION
METHYLPREDNISOLONE SODIUM SUCCINATE

@	STERIS	EQ 125MG BASE/VIAL	N87030 001 JUL 22, 1982
@		EQ 500MG BASE/VIAL	N88523 001 JUL 24, 1984
@		EQ 1GM BASE/VIAL	N88524 001 JUL 24, 1984

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HCL

AP	SMITH AND NEPHEW	**EQ 5MG BASE/ML**	**N70623 001 MAR 02, 1987**
@		EQ 5MG BASE/ML	N70623 001 MAR 02, 1987

METOLAZONE

TABLET; ORAL
ZAROXOLYN

	MEDEVA	2.5MG	N17386 001
+		2.5MG	N17386 001

METOPROLOL TARTRATE

TABLET; ORAL
METOPROLOL TARTRATE

>DLT>	**AB**	PUREPAC PHARM	**50MG**	**N74380 001 JUL 29, 1994**
>DLT>	**AB**		**100MG**	**N74380 002 JUL 29, 1994**
>ADD>	@		50MG	N74380 001 JUL 29, 1994
>ADD>	@		100MG	N74380 002 JUL 29, 1994

METRONIDAZOLE

INJECTABLE; INJECTION
FLAGYL I.V. RTU IN PLASTIC CONTAINER

AP	+	BAXTER HLTHCARE	**500MG/100ML**	**N18657 001**

METRONIDAZOLE

INJECTABLE; INJECTION
FLAGYL I.V. RTU IN PLASTIC CONTAINER

AP	+	SCS	**500MG/100ML**	**N18657 001**

METRONIDAZOLE

AP	STERIS	**500MG/100ML**	**N70170 001 APR 01, 1986**
@		500MG/100ML	N70170 001 APR 01, 1986

MICONAZOLE NITRATE

INSERT, CREAM; VAGINAL, TOPICAL
MONISTAT DUAL- PAK

+	ADVANCED CARE PRODS	1.2GM,2%	N20968 001 JUN 30, 1999

SUPPOSITORY; VAGINAL
MICONAZOLE NITRATE

AB	ALPHARMA US PHARM	**200MG**	**N73508 001 NOV 19, 1993**
AB	NMC	**200MG**	**N73508 001 NOV 19, 1993**

TAMPON; VAGINAL
MONISTAT 5

>DLT>	+	ADVANCED CARE PRODS	100MG	N18592 001 OCT 27, 1989
>ADD>	@		100MG	N18592 001 OCT 27, 1989

MIGLITOL

TABLET; ORAL
GLYSET

>DLT>		BAYER	25MG	N20682 001 DEC 18, 1996
>DLT>			50MG	N20682 002 DEC 18, 1996
>DLT>	+		100MG	N20682 003 DEC 18, 1996
>ADD>		PHARMACIA AND UPJOHN	25MG	N20682 001 DEC 18, 1996
>ADD>			50MG	N20682 002 DEC 18, 1996

MIGLITOL

TABLET; ORAL
GLYSET

> ADD >	+	PHARMACIA AND UPJOHN	100MG	N20682 003 DEC 18, 1996
> ADD >				

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL
MINOCYCLINE HCL

	+	DANBURY PHARMA	EQ 75MG BASE	N63065 002 JUN 10, 1999
AB		GLOBAL PHARM	**EQ 50MG BASE**	**N65005 001** MAR 23, 1999
AB			**EQ 100MG BASE**	**N65005 002** MAR 23, 1999
AB		WARNER CHILCOTT	**EQ 50MG BASE**	**N63066 001** AUG 14, 1990
AB			**EQ 100MG BASE**	**N63067 001** JUL 31, 1990

VECTRIN

AB		WARNER CHILCOTT	**EQ 50MG BASE**	**N63066 001** AUG 14, 1990
> ADD > AB			**EQ 75MG BASE**	**N63067 002** SEP 15, 1999
> ADD > AB			**EQ 100MG BASE**	**N63067 001** JUL 31, 1990

NADOLOL

TABLET; ORAL
CORGARD

AB		APOTHECON	20MG	**N18063 005** OCT 28, 1986
AB			**40MG**	**N18063 001**
AB			**80MG**	**N18063 002**
AB			**120MG**	**N18063 003**
AB	+		**160MG**	**N18063 004**
AB		BRISTOL MYERS SQUIBB	**20MG**	**N18063 005** OCT 28, 1986
AB			**40MG**	**N18063 001**
AB			**80MG**	**N18063 002**
AB			**120MG**	**N18063 003**
AB	+		**160MG**	**N18063 004**

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION
NALOXONE HCL

AP		SMITH AND NEPHEW	**0.02MG/ML**	**N71671 001** NOV 17, 1987
AP			**0.4MG/ML**	**N71681 001** NOV 17, 1987
	@		0.02MG/ML	N71671 001 NOV 17, 1987
	@		0.4MG/ML	N71681 001 NOV 17, 1987
AP		STERIS	**0.4MG/ML**	**N71339 001** NOV 18, 1987
	@		0.4MG/ML	N71339 001 NOV 18, 1987

NALTREXONE HYDROCHLORIDE

TABLET; ORAL
NALTREXONE HCL

AB		AMIDE PHARM	**50MG**	**N75274 001** MAY 26, 1999

NANDROLONE DECANOATE

INJECTABLE; INJECTION
NANDROLONE DECANOATE

AO		STERIS	**50MG/ML**	**N88554 001** FEB 10, 1986
	@		50MG/ML	N88554 001 FEB 10, 1986

NANDROLONE PHENPROPIONATE

INJECTABLE; INJECTION
DURABOLIN

AO	+	ORGANON	**25MG/ML**	**N11891 001**
AO	+		**50MG/ML**	**N11891 002**
	+		25MG/ML	N11891 001
	+		50MG/ML	N11891 002

NANDROLONE PHENPROPIONATE

AO		STERIS	**25MG/ML**	**N86386 001** JUN 17, 1983
AO			**50MG/ML**	**N87488 001** JUN 17, 1983

NANDROLONE PHENPROPIONATE

INJECTABLE; INJECTION
NANDROLONE PHENPROPIONATE

	@ STERIS	25MG/ML	N86386 001 JUN 17, 1983	
	@	50MG/ML	N87488 001 JUN 17, 1983	

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
NAPHAZOLINE HCL

AT	AKORN	**0.1%**	**N83590 001**
AT	TAYLOR	**0.1%**	**N83590 001**

NAPROXEN

TABLET, DELAYED RELEASE; ORAL
NAPROXEN

AB	SIDMAK LABS CA	**375MG**	**N75337 001** MAY 26, 1999
AB		**500MG**	**N75337 002** MAY 26, 1999

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM

>DLT>	**AB**	PUREPAC PHARM	**EQ 250MG BASE**	**N74319 001** MAR 20, 1995
>DLT>	**AB**		**EQ 500MG BASE**	**N74319 002** MAR 20, 1995
>ADD>	@		EQ 250MG BASE	N74319 001 MAR 20, 1995
>ADD>	@		EQ 500MG BASE	N74319 002 MAR 20, 1995

NEDOCROMIL SODIUM

>DLT>		SOLUTION; INHALATION		
>DLT>		TILADE		
>DLT>	+	RHONE POULENC RORER	0.5%	N20750 001 OCT 01, 1997

>ADD> >ADD> >ADD> >ADD>

NEDOCROMIL SODIUM

SOLUTION; INHALATION
TILADE

@	RHONE POULENC RORER	0.5%	N20750 001 OCT 01, 1997

NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; TYROSINE

SUSPENSION; ORAL
TPN SUSPENSION

+	INTL MINERALS	15MG/5ML;3.75MG/5ML; 600MG/5ML	N08378 003
@		15MG/5ML;3.75MG/5ML; 600MG/5ML	N08378 003

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL
PROSTEP

+	ELAN PHARM	11MG/24HR	N19983 001 JAN 28, 1992
+		22MG/24HR	N19983 002 JAN 28, 1992
@		11MG/24HR	N19983 001 JAN 28, 1992
@		22MG/24HR	N19983 002 JAN 28, 1992

NITROGLYCERIN

INJECTABLE; INJECTION
NITROGLYCERIN

AP	SMITH AND NEPHEW	**5MG/ML**	**N70633 001** JUN 19, 1986
@		5MG/ML	N70633 001 JUN 19, 1986

OINTMENT; TRANSDERMAL
NITROGLYCERIN

	ALTANA	2%	N87355 001 JUL 08, 1988
+		2%	N87355 001 JUL 08, 1988

NITROGLYCERIN

SPRAY, METERED; SUBLINGUAL
NITROLINGUAL PUMPSPRAY
+ POHL BOSKAMP 0.4MG/SPRAY N18705 002 JAN 10, 1997

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
PRILOSEC
+ ASTRA PHARMS 10MG N19810 003 OCT 05, 1995
ASTRAZENECA 10MG N19810 003 OCT 05, 1995

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL
ZOFRAN ODT
GLAXO WELLCOME EQ 4MG BASE N20781 001 JAN 27, 1999
+ EQ 8MG BASE N20781 002 JAN 27, 1999

ONDANSETRON HYDROCHLORIDE

TABLET; ORAL
ZOFRAN
+ GLAXO WELLCOME EQ 8MG BASE N20103 002 DEC 31, 1992
EQ 8MG BASE N20103 002 DEC 31, 1992
+ EQ 24MG BASE N20103 003 AUG 27, 1999

ORLISTAT

CAPSULE; ORAL
XENICAL
+ ROCHE 120MG N20766 001 APR 23, 1999

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL
ORPHENADRINE CITRATE
AB KIEL 100MG N40249 001 JAN 29, 1999

OXYBUTYNIN CHLORIDE

SYRUP; ORAL
OXYBUTYNIN CHLORIDE
AA MIKART 5MG/5ML N75039 001 JAN 29, 1999

TABLET, EXTENDED RELEASE; ORAL
DITROPAN XL
+ ALZA 15MG N20897 003 JUN 22, 1999

OXYTETRACYCLINE CALCIUM

SYRUP; ORAL
TERRAMYCIN
+ PFIZER EQ 125MG BASE/5ML N60595 001
@ EQ 125MG BASE/5ML N60595 001

OXYTETRACYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION
TERRAMYCIN
+ PFIZER EQ 250MG BASE/VIAL N60586 001
+ EQ 500MG BASE/VIAL N60586 002
@ EQ 250MG BASE/VIAL N60586 001
@ EQ 500MG BASE/VIAL N60586 002

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT; OTIC
TERRAMYCIN W/ POLYMYXIN
+ PFIZER EQ 5MG BASE/GM; 10,000 UNITS/GM N61841 001
@ EQ 5MG BASE/GM; 10,000 UNITS/GM N61841 001

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

TABLET; VAGINAL
TERRAMYCIN-POLYMYXIN

+	PFIZER	EQ 100MG BASE; 100,000 UNITS	N61009 001	
@		EQ 100MG BASE; 100,000 UNITS	N61009 001	

PAROXETINE HYDROCHLORIDE

CAPSULE; ORAL
PAXIL

	SMITHKLINE BEECHAM	EQ 10MG BASE	N20885 001 OCT 09, 1998	
		EQ 20MG BASE	N20885 002 OCT 09, 1998	
		EQ 30MG BASE	N20885 003 OCT 09, 1998	
+		EQ 40MG BASE	N20885 004 OCT 09, 1998	
@		EQ 10MG BASE	N20885 001 OCT 09, 1998	
@		EQ 20MG BASE	N20885 002 OCT 09, 1998	
@		EQ 30MG BASE	N20885 003 OCT 09, 1998	
@		EQ 40MG BASE	N20885 004 OCT 09, 1998	

TABLET, EXTENDED RELEASE; ORAL
PAXIL CR

+	SMITHKLINE BEECHAM	EQ 12.5MG BASE	N20936 001 FEB 16, 1999	
+		EQ 25MG BASE	N20936 002 FEB 16, 1999	

> ADD > PEMIROLAST POTASSIUM

> ADD > SOLUTION/DROPS; OPHTHALMIC
> ADD > ALAMAST
> ADD > + SANTEN 0.1% N21079 001 SEP 24, 1999
> ADD >

PEMOLINE

TABLET; ORAL
CYLERT

AB	ABBOTT	37.5MG	N16832 002	
AB	+	75MG	N16832 003	
		18.75MG	N16832 001	
		37.5MG	N16832 002	
	+	75MG	N16832 003	
	+	18.75MG	N16832 001	

PEMOLINE

AB	COPLEY PHARM	37.5MG	N75030 001 JAN 29, 1999	
AB		75MG	N75030 002 JAN 29, 1999	
AB	INVAMED	37.5MG	N75286 002 JUN 30, 1999	
AB		75MG	N75286 003 JUN 30, 1999	

PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL
TALWIN 50

> ADD >	@ SANOFI SYNTHELABO	EQ 50MG BASE	N16732 001	
> DLT >	@ STERLING WINTHROP	EQ 50MG BASE	N16732 001	

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL
PENTOXIFYLLINE

AB	IMPAX PHARM	400MG	N75093 001 AUG 10, 1999	
AB	SIDMAK LABS NJ	400MG	N74874 001 MAY 25, 1999	
> ADD > AB	TEVA	400MG	N75199 001 SEP 03, 1999	
> ADD > AB	TORPHARM	400MG	N75191 001 JUN 09, 1999	

PENTOXIL

AB	UPSHER SMITH	400MG	N74962 001 MAR 31, 1999	

PERINDOPRIL ERBUMINE

TABLET; ORAL
ACEON

	@	HUESCHEN	2MG	N20184 001 DEC 30, 1993
	@		4MG	N20184 002 DEC 30, 1993
	@		8MG	N20184 003 DEC 30, 1993
	@	SOLVAY	2MG	N20184 001 DEC 30, 1993
	@		4MG	N20184 002 DEC 30, 1993
	@		8MG	N20184 003 DEC 30, 1993

PHENDIMETRAZINE TARTRATE

CAPSULE; ORAL
PHENAZINE

> DLT >	**AA**	MAST MM	**35MG**	**N86523 001**
> DLT >	**AA**		**35MG**	**N86524 001**
> DLT >	**AA**		**35MG**	**N86525 001**
> ADD >	@		35MG	N86523 001
> ADD >	@		35MG	N86524 001
> ADD >	@		35MG	N86525 001

TABLET; ORAL
PHENAZINE

> DLT >				
> DLT >	**AA**	MAST MM	**35MG**	**N87305 001**
> ADD >	@		35MG	N87305 001

PHENDIMETRAZINE TARTRATE

	AA	MPG CHEMISTS	**35MG**	**N85914 001**
	@		35MG	N85914 001
	AA	PVT FORM	**35MG**	**N85697 001**
	@		35MG	N85697 001

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
FASTIN

	AA	+ SMITHKLINE BEECHAM	**30MG**	**N17352 001**
	@		30MG	N17352 001

PHENTERMINE HCL

	AA	EON	**30MG**	**N86945 001 JUL 20, 1983**

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
PHENTERMINE HCL

	AA	+ EON	**30MG**	**N86945 001 JUL 20, 1983**

PHENYTOIN SODIUM

INJECTABLE; INJECTION
PHENYTOIN SODIUM

	AP	STERIS	**50MG/ML**	**N85434 001**
	@		50MG/ML	N85434 001

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL
ACTOS

		TAKEDA	EQ 15MG BASE	N21073 001 JUL 15, 1999
			EQ 30MG BASE	N21073 002 JUL 15, 1999
	+		EQ 45MG BASE	N21073 003 JUL 15, 1999

POLYETHYLENE GLYCOL 3350

POWDER FOR RECONSTITUTION; ORAL
MIRALAX

	+	BRAINTREE	17GM/SCOOPFUL	N20698 001 FEB 18, 1999

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

	AT	ALCON	**10,000 UNITS/ML; EQ 1MG BASE/ML**	**N64211 001 APR 13, 1998**
	AT	FALCON PHARMS	**10,000 UNITS/ML; EQ 1MG BASE/ML**	**N64211 001 APR 13, 1998**

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

		MICRO-K		
AB		KV PHARM	**8MEQ**	**N18238 001**
AB		ROBINS AH	**8MEQ**	**N18238 001**
		MICRO-K 10		
AB	+	KV PHARM	**10MEQ**	N18238 002 MAY 14, 1984
AB	+	ROBINS AH	**10MEQ**	**N18238 002** **MAY 14, 1984**

GRANULE, FOR RECONSTITUTION ER; ORAL

		MICRO-K LS		
	@	KV PHARM	20MEQ/PACKET	N19561 003 AUG 26, 1988
	@	ROBINS AH	20MEQ/PACKET	N19561 003 AUG 26, 1988

INJECTABLE; INJECTION

		POTASSIUM CHLORIDE		
AP		AM PHARM PARTNERS	**3MEQ/ML**	**N80225 003**
	+		3MEQ/ML	N80225 003
> DLT >	+	MILES	**4MEQ/ML**	**N80195 004**
> ADD >	@		4MEQ/ML	N80195 004
AP		STERIS	**2MEQ/ML**	**N86208 001**
AP			**2MEQ/ML**	**N89163 001** **MAR 10, 1988**
AP			**2MEQ/ML**	**N89421 001** **JAN 02, 1987**
AP	+		**3MEQ/ML**	**N86210 001**
	@		2MEQ/ML	N86208 001
	@		2MEQ/ML	N89163 001 MAR 10, 1988
	@		2MEQ/ML	N89421 001 JAN 02, 1987
	@		3MEQ/ML	N86210 001

POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

INJECTABLE; INJECTION

		THAM-E		
	+	ABBOTT	370MG/VIAL;1.75GM/VIAL; 36GM/VIAL	N13025 001
	@		370MG/VIAL;1.75GM/VIAL; 36GM/VIAL	N13025 001

POTASSIUM CITRATE

POWDER FOR RECONSTITUTION; ORAL

		POTASSIUM CITRATE		
	@	MISSION PHARMA	10MEQ/PACKET	N19647 002 OCT 13, 1988
	@		20MEQ/PACKET	N19647 001 OCT 13, 1988
	@	UNIV TX	10MEQ/PACKET	N19647 002 OCT 13, 1988
	@		20MEQ/PACKET	N19647 001 OCT 13, 1988

POVIDONE-IODINE

SOLUTION/DROPS; OPHTHALMIC

		BETADINE		
	+	ALCON UNIVERSAL	5%	N18634 001 DEC 17, 1986
	+	PURDUE FREDERICK	5%	N18634 001 DEC 17, 1986

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

		PRAZOSIN HCL		
AB		ZENITH GOLDLINE	**EQ 2MG BASE**	**N71995 001** **MAY 16, 1989**
AB			**EQ 2MG BASE**	N71995 001 SEP 12, 1988
AB			**EQ 5MG BASE**	**N71745 001** **MAY 16, 1989**
AB			**EQ 5MG BASE**	**N71745 001** SEP 12, 1988

PREDNISOLONE

SYRUP; ORAL

		PREDNISOLONE		
AA		HALSEY	**15MG/5ML**	**N40287 001** MAY 28, 1999
AA		UDL	**15MG/5ML**	**N40323 001** MAY 13, 1999

PREDNISOLONE ACETATE

INJECTABLE; INJECTION
PREDNISOLONE ACETATE

	+	STERIS	40MG/ML	N83767 001
	@		40MG/ML	N83767 001

SUSPENSION/DROPS; OPHTHALMIC
ECONOPRED PLUS

AB		ALCON	1%	N17469 001
AB		FALCON PHARMS	1%	N17469 001

PREDNISOLONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
HYDELTRASOL

	+	MERCK	EQ 20MG PHOSPHATE/ML	N11583 002
	@		EQ 20MG PHOSPHATE/ML	N11583 002

PREDNISOLONE TEBUTATE

INJECTABLE; INJECTION
HYDELTRA-TBA

BP	+	MERCK	20MG/ML	N10562 001
	@		20MG/ML	N10562 001
	+			
		PREDNISOLONE TEBUTATE		
BP		STERIS	20MG/ML	N83362 001 FEB 17, 1984
	@		20MG/ML	N83362 001 FEB 17, 1984

PREDNISONE

TABLET; ORAL
ORASONE

AB		SOLVAY	50MG	N85999 001
	@		50MG	N85999 001
		PREDNISONE		
> DLT > BX		PHARMAVITE	5MG	N84662 002
> ADD >	@		5MG	N84662 002

PROBENECID

TABLET; ORAL
BENEMID

AB	+	MERCK	500MG	N07898 004

PROBENECID

TABLET; ORAL
BENEMID

	@	MERCK	500MG	N07898 004
		PROBENECID		
AB		MYLAN	500MG	N84211 002
AB	+		500MG	N84211 002

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
PROCAINAMIDE HCL

AP		SMITH AND NEPHEW	100MG/ML	N88530 001 MAR 04, 1985
AP			500MG/ML	N88531 001 MAR 04, 1985
	@		100MG/ML	N88530 001 MAR 04, 1985
	@		500MG/ML	N88531 001 MAR 04, 1985
AP		STERIS	100MG/ML	N87079 001
AP			500MG/ML	N87080 001
	@		100MG/ML	N87079 001
	@		500MG/ML	N87080 001

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE

AP		SMITH AND NEPHEW	EQ 5MG BASE/ML	N89251 001 DEC 04, 1986
	@		EQ 5MG BASE/ML	N89251 001 DEC 04, 1986
AP		STERIS	EQ 5MG BASE/ML	N89606 001 JUL 08, 1987
	@		EQ 5MG BASE/ML	N89606 001 JUL 08, 1987

PROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
PROMAZINE HCL

AP		STERIS	50MG/ML	N84517 001
			25MG/ML	N84510 001
	@		25MG/ML	N84510 001

PROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

		PROMAZINE HCL			
		@ STERIS	50MG/ML		N84517 001
		SPARINE			
AP	+	WYETH AYERST	**50MG/ML**		**N10349 006**
	+		50MG/ML		N10349 006

PROPOFOL

INJECTABLE; INJECTION

		DIPRIVAN			
AB	+	ZENECA	**10MG/ML**		**N19627 002** JUN 11, 1996
	+		10MG/ML		N19627 002 JUN 11, 1996
		PROPOFOL			
AB		GENSIA SICOR PHARMS	**10MG/ML**		**N75102 001** JAN 04, 1999

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

			INDERAL LA			
>DLT>	**AB**	+	WYETH AYERST	**60MG**		**N18553 004** MAR 18, 1987
>DLT>	**AB**	+		**80MG**		**N18553 002** APR 19, 1983
>DLT>	**AB**	+		**120MG**		**N18553 003** APR 19, 1983
>DLT>	**AB**	+		**160MG**		**N18553 001** APR 19, 1983
>ADD>		+		60MG		N18553 004 MAR 18, 1987
>ADD>		+		80MG		N18553 002 APR 19, 1983
>ADD>		+		120MG		N18553 003 APR 19, 1983
>ADD>		+		160MG		N18553 001 APR 19, 1983
>DLT>			**PROPRANOLOL HCL**			
>DLT>	**AB**		INWOOD LABS	**60MG**		**N72499 001** APR 11, 1989
>DLT>	**AB**			**80MG**		**N72500 001** APR 11, 1989

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

>DLT>			**PROPRANOLOL HCL**			
>DLT>	**AB**		INWOOD LABS	**120MG**		**N72501 001** APR 11, 1989
>DLT>	**AB**			**160MG**		**N72502 001** APR 11, 1989
>ADD>		@		60MG		N72499 001 APR 11, 1989
>ADD>		@		80MG		N72500 001 APR 11, 1989
>ADD>		@		120MG		N72501 001 APR 11, 1989
>ADD>		@		160MG		N72502 001 APR 11, 1989

INJECTABLE; INJECTION

		INDERAL			
AP	+	WYETH AYERST	**1MG/ML**		**N16419 001**
	+		1MG/ML		N16419 001
		PROPRANOLOL HCL			
AP		SMITH AND NEPHEW	**1MG/ML**		**N70137 001** APR 15, 1986
	@		1MG/ML		N70137 001 APR 15, 1986

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

		ACIPHEX			
	+	EISAI	20MG		N20973 002 AUG 19, 1999

RANITIDINE BISMUTH CITRATE

TABLET; ORAL

		TRITEC			
>DLT>	+	GLAXO WELLCOME	400MG		N20559 001 AUG 08, 1996
>ADD>	@		400MG		N20559 001 AUG 08, 1996

RANITIDINE HYDROCHLORIDE

TABLET; ORAL
RANITIDINE HCL

AB	GRANUTEC PHARMS	EQ 150MG BASE	N74488 001 JUL 31, 1997
AB		EQ 300MG BASE	N74488 002 JUL 31, 1997
AB	NOVOPHARM NC	EQ 150MG BASE	N74488 001 JUL 31, 1997
AB		EQ 300MG BASE	N74488 002 JUL 31, 1997
AB	PAR PHARM	EQ 150MG BASE	N75180 001 JAN 28, 1999
AB		EQ 300MG BASE	N75180 002 JAN 28, 1999

RAPACURONIUM BROMIDE

INJECTABLE; INJECTION
RAPLON

	ORGANON	100MG/VIAL	N20984 001 AUG 18, 1999
+		200MG/VIAL	N20984 002 AUG 18, 1999

RISPERIDONE

TABLET; ORAL
RISPERDAL

	JANSSEN	0.25MG	N20272 008 MAY 10, 1999
+		0.5MG	N20272 007 JAN 27, 1999

RITONAVIR

CAPSULE; ORAL
NORVIR

	ABBOTT	100MG	N20945 001 JUN 29, 1999

SOLUTION; ORAL
NORVIR

	ABBOTT	80MG/ML	N20659 001 MAR 01, 1996

RITONAVIR

SOLUTION; ORAL
NORVIR

+	ABBOTT	80MG/ML	N20659 001 MAR 01, 1996

ROFECOXIB

SUSPENSION; ORAL
VIOXX

	MERCK	12.5MG/5ML	N21052 001 MAY 20, 1999
+		25MG/5ML	N21052 002 MAY 20, 1999

TABLET; ORAL
VIOXX

	MERCK	12.5MG	N21042 001 MAY 20, 1999
+		25MG	N21042 002 MAY 20, 1999

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL
REQUIP

	SMITHKLINE BEECHAM	EQ 3MG BASE	N20658 006 JAN 27, 1999
		EQ 4MG BASE	N20658 007 JAN 27, 1999

ROSIGLITAZONE MALEATE

TABLET; ORAL
AVANDIA

	SMITHKLINE BEECHAM	EQ 2MG BASE	N21071 002 MAY 25, 1999
		EQ 4MG BASE	N21071 003 MAY 25, 1999
+		EQ 8MG BASE	N21071 004 MAY 25, 1999

SAQUINAVIR

CAPSULE; ORAL
FORTOVASE
+ HLR 200MG N20828 001 NOV 07, 1997
+ ROCHE 200MG N20828 001 NOV 07, 1997

SAQUINAVIR MESYLATE

CAPSULE; ORAL
INVIRASE
+ HLR EQ 200MG BASE N20628 001 DEC 06, 1995
+ ROCHE EQ 200MG BASE N20628 001 DEC 06, 1995

SELEGILINE HYDROCHLORIDE

TABLET; ORAL
ELDEPRYL
® SOMERSET 5MG N19334 001 JUN 05, 1989

SELEGILINE HCL
AB + SOMERSET **5MG** **N19334 001** JUN 05, 1989

SILVER SULFADIAZINE

CREAM; TOPICAL
THERMAZENE
AB KENDALL LP **1%** **N18810 001** DEC 23, 1985
AB SHERWOOD MEDCL **1%** **N18810 001** DEC 23, 1985

>ADD> SIROLIMUS

>ADD> SOLUTION; ORAL
>ADD> RAPAMUNE
>ADD> + WYETH AYERST 1MG/ML N21083 001 SEP 15, 1999
>ADD>

SODIUM PHENYLBUTYRATE

POWDER; ORAL
BUPHENYL
+ MEDICIS 3GM/TEASPOONFUL N20573 001 APR 30, 1996
+ UCYCLYD 3GM/TEASPOONFUL N20573 001 APR 30, 1996

TABLET; ORAL
BUPHENYL
+ MEDICIS 500MG N20572 001 MAY 13, 1996
+ UCYCLYD 500MG N20572 001 MAY 13, 1996

SOMATROPIN, BIOSYNTHETIC

INJECTABLE; INJECTION
HUMATROPE
BX LILLY 6MG/VIAL N19640 005 FEB 04, 1999
+ 12MG/VIAL N19640 006 FEB 04, 1999
+ 24MG/VIAL N19640 007 FEB 04, 1999

SOYBEAN OIL

INJECTABLE; INJECTION
INTRALIPID 10%
AP + FRESENIUS KABI **10%** **N17643 001**
AP + PHARMACIA AND UPJOHN **10%** **N17643 001**
INTRALIPID 20%
AP + FRESENIUS KABI **20%** **N18449 001**
>ADD> **AP** + **20%** **N20248 001** AUG 07, 1996
>ADD> **AP** + PHARMACIA AND UPJOHN **20%** **N18449 001**
>DLT> **AP** + **20%** **N20248 001** AUG 07, 1996
>DLT>
INTRALIPID 30%
AP + FRESENIUS KABI **30%** **N19942 001** DEC 30, 1993
AP + PHARMACIA AND UPJOHN **30%** **N19942 001** DEC 30, 1993

SPIRONOLACTONE

TABLET; ORAL
ALDACTONE

AB	SEARLE	50MG		N12151 008
				DEC 30, 1982
AB	+	100MG		N12151 010
				DEC 30, 1983
		50MG	> ADD >	N12151 008
			> DLT >	DEC 30, 1982
	+	100MG	> ADD >	N12151 010
				DEC 30, 1983

SPIRONOLACTONE

AB	MUTUAL PHARM	50MG		N89424 002
				AUG 11, 1999
AB		100MG		N89424 003
				AUG 11, 1999
AB	PUREPAC PHARM	25MG		N87998 001
				OCT 14, 1983
AB		50MG		N40353 001
				JUL 29, 1999
AB		100MG		N40353 002
				JUL 29, 1999
	@	25MG		N87998 001
				OCT 14, 1983

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
SODIUM SULFACETAMIDE

AT	AKORN	10%	N83021 001
AT		15%	N83021 002
AT		30%	N83021 003
	@	10%	N83021 001
	@	15%	N83021 002
	@	30%	N83021 003

SULFACETAMIDE SODIUM

AT	AKORN	10%	N40215 001
			MAY 25, 1999
AT		30%	N40216 001
			MAY 25, 1999

SULFADIAZINE

TABLET; ORAL
SULFADIAZINE

> DLT >	AB + EON	500MG		N40091 001
> DLT >				JUL 29, 1994

SULFADIAZINE

TABLET; ORAL
SULFADIAZINE

	+ EON	500MG		N40091 001
			> ADD >	JUL 29, 1994
AB	GLOBAL PHARM	500MG	> DLT >	N80081 001
	@	500MG	> ADD >	N80081 001
AB	LANNETT	500MG	> DLT >	N80084 001
	@	500MG	> ADD >	N80084 001

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION
SULFAMETHOXAZOLE AND TRIMETHOPRIM

AP	STERIS	80MG/ML;16MG/ML	N71556 001
			DEC 29, 1987
	@	80MG/ML;16MG/ML	N71556 001
			DEC 29, 1987

TACROLIMUS

CAPSULE; ORAL
PROGRAF

+	FUJISAWA HLTHCARE	EQ 1MG BASE	N50708 001
			APR 08, 1994
		EQ 0.5MG BASE	N50708 003
			AUG 24, 1998
		EQ 1MG BASE	N50708 001
			APR 08, 1994

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION
A-N STANNOUS AGGREGATED ALBUMIN

@	NORTH AM CHEMS	N/A	N17916 001
@	SYNCOR PHARMS	N/A	N17916 001

PULMOLITE

BS	CIS	N/A	N17776 001
BS	DUPONT PHARMS	N/A	N17776 001

TECHNETIUM TC-99M ALBUMIN COLLOID KIT

INJECTABLE; INJECTION
MICROLITE

	CIS	N/A	N18263 001 MAR 25, 1983
	DUPONT PHARMS	N/A	N18263 001 MAR 25, 1983

TECHNETIUM TC-99M DEPREOTIDE

INJECTABLE; INJECTION
NEO TECT KIT

+	DIATIDE	N/A	N21012 001 AUG 03, 1999

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE; INJECTION
HEPATOLITE

	CIS	N/A	N18467 001 MAR 16, 1982
	DUPONT PHARMS	N/A	N18467 001 MAR 16, 1982

TECHNETIUM TC-99M LIDOFENIN KIT

INJECTABLE; INJECTION
TECHNESCAN HIDA

	DRAXIMAGE	N/A	N18489 001 OCT 31, 1986
	@	N/A	N18489 001 OCT 31, 1986

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION
OSTEOLITE

AP	CIS	**N/A**	N17972 001 **N17972 001**
AP	DUPONT PHARMS	**N/A**	

TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT

INJECTABLE; INJECTION
PYROLITE

	CIS	N/A	N17684 001
	DUPONT PHARMS	N/A	N17684 001

TEMOZOLOMIDE

CAPSULE; ORAL
TEMODAR

	SCHERING	5MG	N21029 001 AUG 11, 1999
		20MG	N21029 002 AUG 11, 1999
		100MG	N21029 003 AUG 11, 1999
+		250MG	N21029 004 AUG 11, 1999

TERBUTALINE SULFATE

INJECTABLE; INJECTION
BRETHINE

AP	+ NOVARTIS	**1MG/ML**	**N18571 001**
	+	1MG/ML	N18571 001
	BRICANYL		
AP	+ HOECHST MARION RSSL	**1MG/ML**	**N17466 001**
	@	1MG/ML	N17466 001

TABLET; ORAL
BRETHINE

BP	NOVARTIS	2.5MG	N17849 001
BP	+	5MG	N17849 002
	+	2.5MG	N17849 001
		5MG	N17849 002
	BRICANYL		
BP	HOECHST MARION RSSL	2.5MG	N17618 001
BP		5MG	N17618 002
	@	2.5MG	N17618 001
	@	5MG	N17618 002

TERIPARATIDE ACETATE

INJECTABLE; INJECTION
PARATHAR

+	RHONE POULENC RORER	200 UNITS/VIAL	N19498 001	
			DEC 23, 1987	
@		200 UNITS/VIAL	N19498 001	
			DEC 23, 1987	

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION
TESTOSTERONE ENANTHATE

	STERIS	100MG/ML	N85599 001	
@		100MG/ML	N85599 001	

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
TETRACYCLINE HCL

AB	PUREPAC PHARM	**250MG**	**N60290 001**	
AB		**500MG**	**N60290 002**	
@		250MG	N60290 001	
@		500MG	N60290 002	
	TETRACYN			
AB	PFIPHARMECS	**250MG**	**N60082 003**	>DLT>
AB		**500MG**	**N60082 004**	>DLT>
@		250MG	N60082 003	>DLT>
@		500MG	N60082 004	>ADD>
				>ADD>

THEOPHYLLINE

CAPSULE; ORAL
BRONKODYL

>ADD>	@ SANOFI SYNTHELABO	100MG	N85264 001	
>ADD>	@	200MG	N85264 002	
>DLT>	@ STERLING WINTHROP	100MG	N85264 001	
>DLT>	@	200MG	N85264 002	

CAPSULE, EXTENDED RELEASE; ORAL
THEOCLEAR L.A.-130

BC +	CENT PHARMS	130MG	N86569 001	
			MAY 27, 1982	
@	SCHWARZ PHARMA	130MG	N86569 001	
			MAY 27, 1982	

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL
THEOCLEAR L.A.-260

BC +	CENT PHARMS	260MG	N86569 002	
			MAY 27, 1982	
@	SCHWARZ PHARMA	260MG	N86569 002	
			MAY 27, 1982	

INJECTABLE; INJECTION
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER

@	B BRAUN	40MG/100ML	N19083 001
			NOV 07, 1984
@	MCGAW	40MG/100ML	N19083 001
			NOV 07, 1984

THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER

@	B BRAUN	80MG/100ML	N19083 002
			NOV 07, 1984
@	MCGAW	80MG/100ML	N19083 002
			NOV 07, 1984

THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER

@	B BRAUN	160MG/100ML	N19083 003
			NOV 07, 1984
@	MCGAW	160MG/100ML	N19083 003
			NOV 07, 1984

SYRUP; ORAL
AQUAPHYLLIN

AA	FERNDALE LABS	**80MG/15ML**	**N87917 001**	
			JAN 18, 1983	
@		80MG/15ML	N87917 001	
			JAN 18, 1983	

TABLET, EXTENDED RELEASE; ORAL
SUSTAIRE

BC	ROERIG	100MG	N85665 001
BC		300MG	N85665 002
@		100MG	N85665 001
@		300MG	N85665 002

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL
THIOTHIXENE HCL

AA	ALPHARMA	**EQ 5MG BASE/ML**	**N70969 001**	
			OCT 16, 1987	
@		EQ 5MG BASE/ML	N70969 001	
			OCT 16, 1987	

TIAGABINE HYDROCHLORIDE

TABLET; ORAL
GABITRIL
+ ABBOTT 2MG N20646 005 APR 16, 1999

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL
TICLID
@ ROCHE 125MG N19979 001 MAR 24, 1993
AB + SYNTEX 250MG N19979 002 OCT 31, 1991
@ 125MG N19979 001 MAR 24, 1993
+ SYNTEX USA 250MG N19979 002 OCT 31, 1991

TICLOPIDINE HCL
AB EON 250MG N75326 001 AUG 20, 1999
> ADD > AB GENPHARM 250MG N75161 001 SEP 13, 1999
> ADD >
AB INVAMED 250MG N75318 001 AUG 20, 1999
AB PUREPAC PHARM 250MG N75253 001 AUG 20, 1999
AB TEVA 250MG N75149 001 AUG 20, 1999
AB TORPHARM 250MG N75089 001 JUL 01, 1999

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC
TIMOLOL MALEATE
AB ALCON EQ 0.25% BASE N20963 001 OCT 21, 1998
AB EQ 0.5% BASE N20963 002 OCT 21, 1998
AB FALCON PHARMS EQ 0.25% BASE N20963 001 OCT 21, 1998
AB EQ 0.5% BASE N20963 002 OCT 21, 1998

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC
TIMOLOL MALEATE
AT ADV REMEDIES EQ 0.5% BASE N74466 001 MAR 25, 1997
AT AKORN EQ 0.5% BASE N74466 001 MAR 25, 1997
AT ALCON EQ 0.25% BASE N74261 001 APR 28, 1995
AT EQ 0.5% BASE N74262 001 APR 28, 1995
@ FALCON PHARMS EQ 0.25% BASE N74261 001 APR 28, 1995
@ EQ 0.5% BASE N74262 001 APR 28, 1995

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC
TOBREX
AT + ALCON 0.3% N50541 001
AT + FALCON PHARMS 0.3% N50541 001

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION
TOBRAMYCIN SULFATE
> DLT > AP APOTHECON EQ 40MG BASE/ML N64026 001 MAY 31, 1994
> DLT >
> ADD > @ EQ 40MG BASE/ML N64026 001 MAY 31, 1994
> ADD >

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION
HYCAMTIN
+ SMITHKLINE EQ 4MG BASE/VIAL N20671 001 MAY 28, 1996
+ SMITHKLINE BEECHAM EQ 4MG BASE/VIAL N20671 001 MAY 28, 1996

TRETINOIN

SOLUTION; TOPICAL

		TRETINOIN		
AT		MORTON GROVE	0.05%	N75260 001 JAN 25, 1999

TRIAMCINOLONE

TABLET; ORAL

		TRIAMCINOLONE		
> DLT >	BP	ROXANE	2MG	N84708 001
> DLT >	BP		4MG	N84709 001
> DLT >	BP		8MG	N84707 001
> ADD >		@	2MG	N84708 001
> ADD >		@	4MG	N84709 001
> ADD >		@	8MG	N84707 001
> DLT >	BP	TEVA	4MG	N84775 001
> ADD >		@	4MG	N84775 001

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

		ARISTOCORT		
AT		FUJISAWA HLTHCARE	0.025%	N83017 003
AT			0.1%	N83016 004
AT			0.5%	N83015 002
AT		LEDERLE	0.025%	N83017 003
AT			0.1%	N83016 004
AT			0.5%	N83015 002
		ARISTOCORT A		
AT		FUJISAWA HLTHCARE	0.025%	N83017 004
AT			0.025%	N88818 001 OCT 16, 1984
AT			0.1%	N83016 005
AT			0.1%	N88819 001 OCT 16, 1984
AT			0.5%	N83015 003
AT			0.5%	N88820 001 OCT 16, 1984
AT		LEDERLE	0.025%	N83017 004
AT			0.025%	N88818 001 OCT 16, 1984
AT			0.1%	N83016 005
AT			0.1%	N88819 001 OCT 16, 1984
AT			0.5%	N83015 003

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

		ARISTOCORT A		
AT		LEDERLE	0.5%	N88820 001 OCT 16, 1984

GEL; TOPICAL

		ARISTOGEL		
		@ FUJISAWA HLTHCARE	0.1%	N83380 001
		@ LEDERLE	0.1%	N83380 001

OINTMENT; TOPICAL

		ARISTOCORT		
AT		FUJISAWA HLTHCARE	0.1%	N80750 004
AT			0.5%	N80745 002
AT		LEDERLE	0.1%	N80750 004
AT			0.5%	N80745 002
		ARISTOCORT A		
AT		FUJISAWA HLTHCARE	0.1%	N80750 003
AT			0.1%	N88780 001 OCT 01, 1984
AT	+		0.5%	N80745 003
	@		0.5%	N88781 001 OCT 05, 1984
AT		LEDERLE	0.1%	N80750 003
AT			0.1%	N88780 001 OCT 01, 1984
AT	+		0.5%	N80745 003
	@		0.5%	N88781 001 OCT 05, 1984
		TRIAMCINOLONE ACETONIDE		
AT		ALPHARMA	0.5%	N89913 001 DEC 23, 1988
	@		0.5%	N89913 001 DEC 23, 1988

TRIAMCINOLONE DIACETATE

SYRUP; ORAL

	ARISTOCORT		
	FUJISAWA HLTHCARE	2MG/5ML	N11960 004
	LEDERLE	2MG/5ML	N11960 004

TRICHLORMETHIAZIDE

TABLET; ORAL

> DLT >		TRICHLORMAS			
> DLT >	BP	MAST MM	4MG		N86259 001
> ADD >		@	4MG		N86259 001

TRIHEXYPHENIDYL HYDROCHLORIDE

ELIXIR; ORAL

		TRIHEXYPHENIDYL HCL		
> ADD >	AA	MIKART	2MG/5ML	N40251 001
> ADD >				SEP 27, 1999

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

		TRIMETHOBENZAMIDE HCL		
AP		SMITH AND NEPHEW	100MG/ML	N88960 001
				APR 04, 1986
		@	100MG/ML	N88960 001
				APR 04, 1986

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

TABLET; ORAL

		SULFA-TRIPLE #2		
AB	+	GLOBAL PHARM	167MG;167MG;167MG	N80079 001
		@	167MG;167MG;167MG	N80079 001
		TRIPLE SULFOID		
AB		PAL PAK	167MG;167MG;167MG	N80094 001
		+	167MG;167MG;167MG	N80094 001

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

		TROPICAMIDE		
AT		STERIS	0.5%	N89171 001
				DEC 28, 1990
		@	0.5%	N89171 001
				DEC 28, 1990

UREA, C-13

POWDER FOR RECONSTITUTION; ORAL

		PYLORI-CHEK BREATH TEST		
	+	ALIMENTERICS	100MG/VIAL	N20900 001
				FEB 04, 1999

VALRUBICIN

SOLUTION;

		VALSTAR PRESERVATIVE FREE		
	+	ANTHRA	40MG/ML	N20892 001
				SEP 25, 1998

SOLUTION; INTRAVESICAL

		VALSTAR PRESERVATIVE FREE		
	+	ANTHRA	40MG/ML	N20892 001
				SEP 25, 1998

VECURONIUM BROMIDE

INJECTABLE; INJECTION

		VECURONIUM BROMIDE		
AP		ESI LEDERLE	10MG/VIAL	N75218 001
				AUG 23, 1999
AP			20MG/VIAL	N75218 002
				AUG 23, 1999
AP		GENSIA	10MG/VIAL	N74688 001
				AUG 25, 1999
AP			20MG/VIAL	N74688 002
				AUG 25, 1999

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

		VERAPAMIL HCL		
AB		MYLAN	120MG	N75138 001
				APR 20, 1999
AB			180MG	N75138 002
				APR 20, 1999
AB			240MG	N75138 003
				APR 20, 1999
		VERELAN		
	+	ELAN	120MG	N19614 001
				MAY 29, 1990

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VERELAN

	+	ELAN	180MG	N19614 003 JAN 09, 1992
	+		240MG	N19614 002 MAY 29, 1990
AB	+	ELAN PHARM	120MG	N19614 001 MAY 29, 1990
AB	+		180MG	N19614 003 JAN 09, 1992
AB	+		240MG	N19614 002 MAY 29, 1990

INJECTABLE; INJECTION

VERAPAMIL HCL

AP		SMITH AND NEPHEW	2.5MG/ML	N70696 001 JUL 31, 1987
	@		2.5MG/ML	N70696 001 JUL 31, 1987

TABLET, EXTENDED RELEASE; ORAL

VERAPAMIL HCL

AB		DURAMED	120MG	N75072 001 MAY 25, 1999
AB			240MG	N75072 003 MAY 25, 1999

VINCRISTINE SULFATE

INJECTABLE; INJECTION

VINCRISTINE SULFATE PFS

> ADD >	AP		GENSIA SICOR PHARMS	1MG/ML	N75493 001 SEP 01, 1999
> ADD >					

VITAMIN A PALMITATE

CAPSULE; ORAL

DEL-VI-A

> DLT >					
> DLT >	AA		DEL RAY LABS	EQ 50,000 UNITS BASE	N80830 001
> ADD >		@		EQ 50,000 UNITS BASE	N80830 001

WARFARIN SODIUM

TABLET; ORAL

COUMADIN

AB	+	DUPONT MERCK	2MG	N09218 013
AB			2MG	N09218 013
AB			2.5MG	N09218 018
AB	+		2.5MG	N09218 018
AB			5MG	N09218 007
AB	+		5MG	N09218 007

WARFARIN SODIUM

AB	TARO	1MG	N40301 002 JUL 15, 1999
AB		2MG	N40301 003 JUL 15, 1999
AB		2.5MG	N40301 004 JUL 15, 1999
AB		3MG	N40301 005 JUL 15, 1999
AB		4MG	N40301 006 JUL 15, 1999
AB		5MG	N40301 007 JUL 15, 1999
AB		6MG	N40301 008 JUL 15, 1999
AB		7.5MG	N40301 009 JUL 15, 1999
AB		10MG	N40301 001 JUL 15, 1999

XYLOSE

POWDER; ORAL

XYLO-PFAN

AA	+	SAVAGE LABS	25GM/BOT	N17605 001
	@		25GM/BOT	N17605 001

XYLOSE

AA		LYNE	25GM/BOT	N18856 001 MAR 26, 1987
	+		25GM/BOT	N18856 001 MAR 26, 1987

ZALEPLON

CAPSULE; ORAL

SONATA

		WYETH AYERST	5MG	N20859 001 AUG 13, 1999

ZALEPLON

CAPSULE; ORAL
SONATA
+ WYETH AYERST 10MG N20859 002
AUG 13, 1999

ZANAMIVIR

CAPSULE; INHALATION
RELENZA
+ GLAXO WELLCOME 5MG N21036 001
JUL 26, 1999

ACETAMINOPHEN

SUPPOSITORY; RECTAL

	ACEPHEN		
+	G AND W LABS	120MG	N18060 001
+		325MG	N18060 003 DEC 18, 1986
+		650MG	N18060 002
		120MG	N18060 001
		325MG	N18060 003 DEC 18, 1986
		650MG	N18060 002
	ACETAMINOPHEN		
	ASCENT PEDS	120MG	N18337 003 SEP 12, 1983
		325MG	N18337 002
+		650MG	N18337 001
	UPSHER SMITH	120MG	N18337 003 SEP 12, 1983
		325MG	N18337 002
		650MG	N18337 001
	INFANTS' FEVERALL		
	ASCENT PEDS	80MG	N18337 004 AUG 26, 1992
	UPSHER SMITH	80MG	N18337 004 AUG 26, 1992

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	CONTAC		
+	SMITHKLINE	8MG;75MG	N18099 001
@		8MG;75MG	N18099 001
	PHENYLPROPANOLAMINE HCL W/ CHLORPHENIRAMINE MALEATE		
	CENT PHARMS	8MG;75MG	N18809 001 MAY 07, 1984
+		8MG;75MG	N18809 001 MAY 07, 1984

TABLET, EXTENDED RELEASE; ORAL

	CONTAC		
	NOVARTIS	12MG;75MG	N19613 001 JUN 13, 1986
+		12MG;75MG	N19613 001 JUN 13, 1986
	TRIAMINIC-12		
+	NOVARTIS	12MG;75MG	N18115 001
@		12MG;75MG	N18115 001

CIMETIDINE

SUSPENSION; ORAL

	TAGAMET HB 200		
+	SMITHKLINE BEECHAM	200MG/20ML	N20951 001 JUL 09, 1999

TABLET; ORAL

	CIMETIDINE		
	DANBURY PHARMA	200MG	N75425 001 JUL 29, 1999
	ZENITH GOLDLINE	200MG	N75345 001 JUN 16, 1999

CLOTRIMAZOLE

CREAM; TOPICAL

	LOTRIMIN AF		
	SCHERING PLOUGH	1%	N17619 002 OCT 27, 1989

LOTION; TOPICAL

	LOTRIMIN AF		
	SCHERING	1%	N18813 002 OCT 27, 1989

SOLUTION; TOPICAL

	LOTRIMIN AF		
	SCHERING PLOUGH	1%	N17613 002 OCT 27, 1989

EPINEPHRINE BITARTRATE

AEROSOL, METERED; INHALATION

	MEDIHALER-EPI		
+	3M	0.3MG/INH	N10374 003
@		0.3MG/INH	N10374 003

FAMOTIDINE

TABLET; ORAL

	PEPCID AC		
	MERCK	10MG	N20902 001 AUG 05, 1999

IBUPROFEN

SUSPENSION; ORAL
IBUPROFEN
ALPHARMA 100MG/5ML N74916 001 APR 30, 1999

TABLET; ORAL
IBUPROFEN
LNK 200MG N75010 001 MAR 01, 1999
200MG N75139 001 MAR 01, 1999
NORTON HN 200MG N71144 001 JAN 20, 1987
200MG N72901 001 DEC 19, 1991
200MG N72903 001 DEC 19, 1991
ZENITH GOLDLINE 200MG N71144 001 JAN 20, 1987
200MG N72901 001 DEC 19, 1991
200MG N72903 001 DEC 19, 1991

JUNIOR STRENGTH IBUPROFEN
PERRIGO 100MG N75367 001 APR 22, 1999

IBUPROFEN POTASSIUM

CAPSULE; ORAL
PROVEL
+ NOVARTIS 200MG N20402 001 APR 20, 1995
+ WHITEHALL ROBINS 200MG N20402 001 APR 20, 1995

INSULIN ZINC SUSP PURIFIED BEEF

INJECTABLE; INJECTION
LENTE ILETIN II
+ LILLY 100 UNITS/ML N18477 001
@ 100 UNITS/ML N18477 001

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL
M-ZOLE 3 COMBINATION PACK
ALPHARMA US PHARM 2%,200MG N74926 001 APR 16, 1999

MICONAZOLE NITRATE COMBINATION PACK
PERRIGO 2%,200MG N75329 001 APR 20, 1999

SUPPOSITORY; VAGINAL
MICONAZOLE NITRATE
ALPHARMA US PHARM 100MG N73507 001 NOV 19, 1993
NMC 100MG N73507 001 NOV 19, 1993

MINOXIDIL

SOLUTION; TOPICAL
MINOXIDIL (FOR MEN)
PERRIGO 2% N75357 001 JUL 30, 1999

MINOXIDIL (FOR WOMEN)
PERRIGO 2% N75357 002 JUL 30, 1999

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM
GRANUTEC EQ 200MG BASE N74635 001 JAN 13, 1997
NOVOPHARM NC EQ 200MG BASE N74635 001 JAN 13, 1997

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL
PROSTEP
+ ELAN PHARM 11MG/24HR N19983 003 DEC 23, 1998
+ 22MG/24HR N19983 004 DEC 23, 1998

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICOTINE POLACRILEX		
WATSON LAB	EQ 2MG BASE	N74507 001 MAR 15, 1999
	EQ 4MG BASE	N74707 001 MAR 19, 1999

NONOXYNOL-9

SPONGE; VAGINAL

TODAY		
@ ALLENDALE PHARMS	1GM	N18683 001 APR 01, 1983
@ WHITEHALL ROBINS	1GM	N18683 001 APR 01, 1983

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PSEUDOEPHEDRINE HCL		
PERRIGO	120MG	N75153 001 FEB 26, 1999

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HCL		
NOVOPHARM	EQ 75MG BASE	N75094 001 JUN 21, 1999
RANBAXY	EQ 75MG BASE	N75132 001
ZANTAC 75		
+ GLAXO WELLCOME	EQ 75MG BASE	N20520 001 DEC 19, 1995
+ WARNER LAMBERT	EQ 75MG BASE	N20520 001 DEC 19, 1995

TERBINAFINE HYDROCHLORIDE

CREAM; TOPICAL

LAMISIL		
+ NOVARTIS	1%	N20980 001 MAR 09, 1999

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 9 SEP '99

NO SEPTEMBER 1999 APPROVALS

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Product Designations and Approvals List
September 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
111Indium pentetreotide TN= SomatoTher	Treatment of somatostatin receptor positive neuroendocrine tumors.	Louisiana State University Medical Center Foundation 1600 Canal St. 10th Floor New Orleans, LA 70112 DD=06/10/1999
166Ho-DOTMP TN=	Treatment of multiple myeloma.	NeoRx Corporation 410 W. Harrison Seattle, WA 98119 DD=02/10/1999
506U78 TN=	Treatment of chronic lymphocytic leukemia.	Glaxo Wellcome, Inc. Five Moore Dr. P.O. Box 13398 Durham, NC 27709 DD=09/02/1999
6-hydroxymethylacylfulvene TN=	Treatment of histologically confirmed advanced or metastatic pancreatic cancer.	MGI Pharma, Inc. 6300 West Old Shakoppe Rd. Suite 110 Bloomington, MN 55438 DD=04/06/1999
6-hydroxymethylacylfulvene TN=	Treatment of ovarian cancer.	MGI Pharma, Inc. 6300 West Old Shakoppe Rd. Suite 110 Bloomington, MN 55438 DD=07/06/1999

Orphan Product Designations and Approvals List
September 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
6-hydroxymethylacylfulvene TN=	Treatment of renal cell carcinoma.	MGI Pharma, Inc. 6300 West Old Shakoppe Rd. Suite 110 Bloomington, MN 55438 DD=07/27/1999
Alitretinoin TN= Panretin	Topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.	Ligand Pharmaceuticals Inc. 10275 Science Center Drive San Diego, CA 92121 DD=03/24/1998 MA=02/02/1999
Amifostine TN= Ethyol	Reduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.	U.S. Bioscience, Inc. One Tower Bridge 100 Front Street, Suite 400 Conshohocken, PA 19428 DD=05/12/1998 MA=06/24/1999
Antihemophilic factor/von Willebrand factor complex (human), dried, pasteurized TN= Humate-P	Treatment and prevention of bleeding in hemophilia A (classical hemophilia) in adult patients; and treatment of spontaneous and trauma-induced bleeding episodes in severe von Willebrand disease, and in mild and moderate von Willebrand disease where use of desmopressin is known or suspected to be inadequate in adult and pediatric patients.	Centeon Pharma GmbH Emil-von-Behring-Strasse 76 35041 Marburg Germany DD=10/16/1992 MA=04/01/1999

Orphan Product Designations and Approvals List
September 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Artesunate TN=	Treatment of malaria.	World Health Organisation Special Programme for Research and Training in Tropical Diseases Via Appia Geneva 27, Switzerland DD=07/19/1999
Atovaquone TN= Mepron	Prevention of Pneumocystis carinii pneumonia (PCP) in high-risk, HIV-infected patients defined by a history of one or more episodes of PCP and/or a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm3.	Glaxo Wellcome Research and Development 5 Moore Drive PO Box 13398 Research Triangle Park, NC 27709 DD=08/14/1991 MA=01/05/1999
Autologous DNP-conjugated tumor vaccine TN= M-Vax	For adjuvant therapy in melanoma patients with surgically resectable lymph node metastasis (Stage III and limited Stage IV disease).	Avax Technologies, Inc. 4520 Main St. Suite 930 Kansas City, MO 64111 DD=02/23/1999
Azathioprine TN= Imuran	Treatment of oral manifestations of graft-versus-host disease.	Oral Solutions, Inc. 787 Seventh Ave., 48th Floor New York, NY 10019 DD=09/14/1999
Beraprost TN=	Treatment of pulmonary arterial hypertension associated with any New York Heart Association classification (Class I, II, III, or IV).	United Therapeutics Corporation 68 T.W. Alexander Drive, PO Box 14186 Research Triangle Park, NC 27709 DD=04/29/1999

Orphan Product Designations and Approvals List
September 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Bexarotene TN= Targretin	Treatment of cutaneous T-cell lymphoma.	Ligand Pharmaceuticals, Inc. 10275 Science Center Dr. San Diego, CA 92121 DD=06/18/1999
Bleomycin TN= Blenoxane	Treatment of pancreatic cancer.	Genetronics, Inc. 11199 Sorrento Valley Rd. San Diego, CA 92121 DD=02/09/1999
Busulfan TN= Busulfex	As preparative therapy in the treatment of malignancies with bone marrow transplantation.	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 475 Minnetonka, MN 55305 DD=07/28/1994 MA=02/04/1999
CT-2584 mesylate TN=	Treatment of adult soft tissue sarcoma.	Cell Therapeutics, Inc. 201 Elliott Ave. West Suite 400 Seattle, WA 98119 DD=04/16/1999
CT-2584 mesylate TN=	Treatment of malignant mesothelioma.	Cell Therapeutics, Inc. 201 Elliott Ave. West Seattle, WA 98119 DD=04/16/1999
Caffeine TN= Cafcit	Treatment of apnea of prematurity.	O.P.R. Development, L.P. 1501 Wakarusa Drive Lawrence, KS 66047 DD=09/20/1988 MA=09/21/1999

Orphan Product Designations and Approvals List
September 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Coagulation factor VIIa (recombinant) TN= NovoSeven	Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.	Novo Nordisk Pharmaceuticals, Inc. 100 Overlook Center Suite 200 Princeton, NJ 08540 DD=06/06/1988 MA=03/25/1999
Cytarabine liposomal TN= DepoCyt	Treatment of neoplastic meningitis.	DepoTech Corporation 10450 Science Center Drive San Diego, CA 92121 DD=06/02/1993 MA=04/01/1999
Decitabine TN=	Treatment of myelodysplastic syndromes.	Pharmachemie B.V. Swensweg 5 2031 GA Haarlem, The Netherlands DD=03/08/1999
Decitabine TN=	Treatment of chronic myelogenous leukemia.	Pharmachemie B.V. Swensweg 5 2031 GA Haarlem, The Netherlands DD=03/08/1999
Denileukin diftitox TN= Ontak	Treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor.	Seragen, Inc. 97 South Street Hopkinton, MA 01748 DD=08/21/1996 MA=02/05/1999
Doxorubicin liposome TN= Doxil	Treatment of ovarian cancer.	Alza Corporation 1550 Plymouth St. PO Box 7210 Mountain View, CA 94039 DD=11/04/1998 MA=06/28/1999

Orphan Product Designations and Approvals List
September 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Epirubicin TN= Ellence	Treatment of breast cancer.	Pharmacia & Upjohn Company 0634-298-113 7000 Portage Rd. Kalamazoo, MI 49001 DD=09/14/1999 MA=09/15/1999
Epoprostenol TN= Flolan	Treatment of secondary pulmonary hypertension due to intrinsic precapillary pulmonary vascular disease.	Glaxo Wellcome Inc. Five Moore Dr. PO Box 13398 Research Triangle Park, NC 27709 DD=03/22/1999
Etanercept TN= Enbrel	Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.	Immunex Corporation 51 University St. Seattle, WA 98101 DD=10/27/1998 MA=05/27/1999
Etanercept TN= Enbrel	Treatment of Wegener's granulomatosis.	Stone, MD, MPH, John H. Johns Hopkins Vasculitis Center, Division of Rheumatology 1830 East Monument St., Suite 7500 Baltimore, MD 21205 DD=04/06/1999

Orphan Product Designations and Approvals List
September 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Fluoxetine TN= Prozac	Treatment of autism.	Hollander, MD, Eric Mt. Sinai School of Medicine, Dept. of Psychiatry Box 1230, One Gustave L. Levy Place New York, NY 10029 DD=04/30/1999
Guanfacine TN= Tenex	Treatment of fragile X syndrome.	Watson Laboratories, Inc. 311 Bonnie Circle PO Box 1900 Corona, CA 91718 DD=08/05/1999
HLA-B7/Beta2M DNA Lipid (DMRIE/DOPE) Complex TN= Allovectin-7	Treatment of invasive and metastatic melanoma (Stages II, III, and IV).	Vical Incorporated 9373 Towne Centre Dr., Suite 100 San Diego, CA 92121 DD=09/30/1999
Humanized MAb (IDEC-131) to CD40L TN=	Treatment of systemic lupus erythematosus.	Idec Pharmaceuticals Corporation 3030 Callan Rd. San Diego, CA 92121 DD=02/09/1999
Interferon beta-1a (recombinant human) TN= Avonex	Treatment of pulmonary fibrosis.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=01/07/1999
Iodine I-131 radiolabeled chimeric MAb tumor necrosis treatment (TNT-1B) TN= 131IchTNT-1	Treatment of glioblastoma multiforme and anaplastic astrocytoma.	Techniclone Corporation 14282 Franklin Ave. Tustin, CA 92780 DD=02/12/1999

Orphan Product Designations and Approvals List
September 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Japanese encephalitis vaccine (live, attenuated) TN=	Prevention of Japanese encephalitis.	Boran Pharmaceuticals 3F, Koryo Academytel, 437-3 Ahyun-Dong, Mapo-Gu, Seoul 121-010 South Korea DD=05/19/1999
L-5-hydroxytryptophan TN=	Treatment of tetrahydrobiopterin deficiency.	Watson Laboratories, Inc. 311 Bonnie Circle P.O. Box 1900 Corona, CA 91718 DD=01/20/1999
Lactic acid TN= Aphthaid	Treatment of severe aphthous stomatitis in severely, terminally immunocompromised patients.	Frontier Pharmaceutical, Inc. SUNY Farmingdale Conklin Hall Farmingdale, NY 11735 DD=06/29/1999
Lidocaine patch 5% TN= Lidoderm Patch	For relief of allodynia (painful hypersensitivity), and chronic pain in post-herpetic neuralgia.	Hind Health Care, Inc. 3707 Williams Rd., Suite 101 San Jose, CA 95117 DD=10/24/1995 MA=03/19/1999
Liposomal-cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane-Pt (II) TN=	Treatment of malignant mesothelioma.	Aronex Pharmaceuticals, Inc. 8707 Technolgoy Forest Place The Woodlands, TX 77381 DD=09/01/1999

Orphan Product Designations and Approvals List
September 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Lisofylline TN=	Treatment of patients undergoing induction therapy for acute myeloid leukemia.	Cell Therapeutics, Inc. 201 Elliot Ave. W., Suite 400 Seattle, WA 98119 DD=06/10/1999
Marijuana TN=	Treatment of HIV-associated wasting syndrome.	Multidisciplinary Association for Psychedelic Studies, Inc. 3 Francis St. Belmont, MA 02478 DD=05/25/1999
Mitoxantrone TN= Novantrone	Treatment of secondary-progressive multiple sclerosis.	Immunex Corporation 51 University St. Seattle, WA 98101 DD=08/13/1999
Mitoxantrone TN= Novantrone	Treatment of progressive-relapsing multiple sclerosis.	Immunex Corporation 51 University St. Seattle, WA 98101 DD=08/13/1999
Murine MAb to polymorphic epithelial mucin, human milk fat globule 1 TN= Theragyn	Adjuvant treatment of ovarian cancer.	Antisoma West Africa House Hanger Lane London W5 3QR, UK DD=03/22/1999
N-acetylgalactosamine-4-sulfatase, recombinant human TN=	Treatment of mucopolysaccharidosis Type VI (Maroteaux-Lamy syndrome).	BioMarin Pharmaceutical, Inc. 11 Pimental Court Novato, CA 94949 DD=02/17/1999

Orphan Product Designations and Approvals List
September 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Parovirus B19 (recombinant VP1 and VP2; S.frugiperda cells) vaccine TN= MEDI-491	Prevention of transient aplastic crisis in patients with sickle cell anemia.	MedImmune, Inc. 35 West Watkins Mill Rd. Gaithersburg, MD 20878 DD=05/07/1999
Peginterferon alfa-2a TN= PEGASYS	Treatment of chronic myelogenous leukemia.	Hoffman-La Roche Inc. 340 Kingsland St. Nutley, NJ 07110 DD=09/30/1999
Pegylated arginine deiminase TN= Hepacid	Treatment of hepatocellular carcinoma.	Phoenix Pharmacologics, Inc. 115 John Robert Thomas Dr. Exton, PA 19341 DD=03/26/1999
Pegylated arginine deiminase TN= Melanocid	Treatment of invasive malignant melanoma.	Phoenix Pharmacologics, Inc. 115 John Robert Thomas Dr. Exton, PA 19341 DD=04/12/1999
Polyethylene glycol-modified uricase TN= Zurase	Prophylaxis of hyperuricemia in cancer patients prone to develop tumor lysis syndrome during chemotherapy.	Phoenix Pharmacologics, Inc. 115 John Robert Thomas Dr. Exton, PA 19341 DD=09/14/1999
Recombinant human C1-esterase inhibitor TN=	Prophylactic treatment of angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Pharming N.V. Cipalstreet 3 B-2440 Geel, Belgium DD=02/23/1999

Orphan Product Designations and Approvals List
September 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Recombinant human C1-esterase inhibitor TN=	Treatment of (acute attacks of) angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Pharming N.V. Cipalstreet 3 B-2440 Geel, Belgium DD=02/23/1999
Recombinant human insulin-like growth factor-I/insulin -like growth factor binding protein-3 TN=	Treatment of major burns that require hospitalization.	Celtrix Pharmaceuticals, Inc. 3055 Patrick Henry Dr. Santa Clara, CA 95054 DD=06/15/1999
Recombinant human nerve growth factor TN=	Treatment of HIV-associated sensory neuropathy.	Genentech, Inc. 1 DNA Way South San Francisco, CA 94080 DD=04/16/1999
Recombinant humanized MAb 5c8 TN=	Prevention of rejection of solid organ transplants.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=03/22/1999
Recombinant humanized MAb 5c8 TN=	Prevention of rejection of pancreatic islet cell transplants.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=03/22/1999
Rifalazil TN=	Treatment of pulmonary tuberculosis.	PathoGenesis Corporation 201 Elliott Avenue West Suite 150 Seattle, WA 98119 DD=04/13/1999

Orphan Product Designations and Approvals List
September 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
SCH 58500 TN=	Treatment of primary ovarian cancer.	Schering Corporation 2000 Galloping Hill Rd. Kenilworth, NJ 07033 DD=04/12/1999
Sodium 1,3-propanedisulfonate TN=	Treatment of secondary amyloidosis.	Neurochem, Inc. 7220 Frederick Banting, Suite 100 Saint-Laurent, Quebec Canada H4S 2A1 DD=04/06/1999
Sodium dichloroacetate TN= Ceresine	Treatment of severe head injury.	Cypros Pharmaceutical Corporation 2714 Loker Avenue West Carlsbad, CA 92008 DD=06/14/1999
Somatropin [rDNA] TN= Genotropin	Treatment of short stature in patients with Prader-Willi syndrome.	Pharmacia & Upjohn 7000 Portage Rd. 0633-298-113 Kalamazoo, MI 49001 DD=07/06/1999
Synthetic human secretin TN=	For use in the evaluation of exocrine pancreas function.	ChiRhoClin, Inc. 1550 Gallaudet Ave. Silver Spring, MD 20905 DD=06/16/1999
Synthetic human secretin TN=	For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring, MD 20905 DD=06/16/1999

Orphan Product Designations and Approvals List
September 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Synthetic human secretin TN=	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring, MD 20905 DD=06/16/1999
Synthetic porcine secretin TN=	For use in the evaluation of exocrine pancreas function.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring, MD 20905 DD=06/18/1999
Synthetic porcine secretin TN=	For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring, MD 20905 DD=06/18/1999
Synthetic porcine secretin TN=	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring, MD 20905 DD=06/18/1999
Temozolomide TN= Temodar	Treatment of recurrent malignant glioma.	Schering-Plough Research Institute 2000 Galloping Hill Rd. Kenilworth, NJ 07033 DD=10/05/1998 MA=08/11/1999
Thalidomide TN= Thalomid	Treatment of Crohn's disease.	Celgene Corporation 7 Powder Horn Dr. Warren, NJ 07059 DD=04/06/1999

Orphan Product Designations and Approvals List
September 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Tobramycin TN= Tobi	Treatment of bronchiectasis patients infected with Pseudomonas aeruginosa.	PathoGenesis Corporation 201 Elliott Avenue West Suite 150 Seattle, WA 98119 DD=06/18/1999
Transgenic human alpha 1 antitrypsin TN=	Treatment of emphysema secondary to alpha 1 antitrypsin deficiency.	PPL Therapeutics (Scotland) Limited Roslin, Edinburgh EH25 9PP Scotland U.K. DD=05/19/1999
Yttrium-90 radiolabeled humanized monoclonal anti-carcinoembryonic antigen IgG antibody TN= Cea-Cide	Treatment of ovarian carcinoma.	Immunomedics, Inc. 300 American Rd. Morris Plains, NJ 07950 DD=08/03/1999

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO SEPTEMBER 1999 ADDITIONS

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 19TH EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION.

ABBREVIATIONS

NP* NEW PRODUCT (MINT FLAVORED)

REFERENCES

NEW DOSING SCHEDULE

D-50 INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS

NEW INDICATION

I-250 PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPTOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C

I-251 TREATMENT OF GENERALIZED ANXIETY DISORDER

I-252 NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN

I-253 COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN

I-254 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS)

I-255 PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP)

I-256 USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY

I-257 TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMMATION

I-258 FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES FOUR AND ABOVE

I-259 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY

I-260 EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER)

I-261 TREATMENT OF SOCIAL ANXIETY DISORDER

I-262 TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12

I-263 TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY

I-264 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION

I-265 TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER

I-266 USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES

I-267 USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER-FOR CORTICOSTEROID-RESPONSIVE DERMATOSES

I-268 PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE

PATENT AND EXCLUSIVITY TERMS

NEW INDICATION

I-269	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN
I-270	ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY
I-271	TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-272	TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOIDS IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY
I-273	ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
I-274	USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES

REFERENCES

MISCELLANEOUS EXCLUSIVITY CODES

M-1	INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION

PATENT USE CODE

U-254	USE OF AGGRASTAT IN COMBINATION WITH HEPARIN
U-255	IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY
U-256	TREATMENT OF HIV INFECITON IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS
U-257	TREATMENT OF HIV INFECTION
U-258	TREATMENT OF NEURODEGENERATIVE DISEASES
U-259	TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION OF DRUG SUBSTANCE
U-260	REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION
U-261	TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE
U-262	TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE
U-263	METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN.
U-264	METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN.
U-265	USE AS A LAXATIVE
U-266	OSTEOARTHRITIS
U-267	METHOD FOR PREVENTING HEARTBURN
U-268	ACROMEGALY
U-269	EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS
U-270	METHOD FOR IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT
U-271	METHOD OF TREATING TUMORS
U-272	METHOD OF TREATING CARCINOMA

PATENT AND EXCLUSIVITY TERMS

PATENT USE CODE

U-273	CUTANEOUS T-CELL LYMPHOMA
U-274	ZANAMIVIR FOR INHALATION
U-275	METHOD OF USE OF THE DRUG SUBSTANCE
U-276	METHOD OF USE OF LEVOBUPIVACAINE
U-277	NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)
U-278	METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT
U-279	METHOD OF USE OF THE APPROVED PRODUCT
U-280	TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE
U-281	ANTIMYCOTIC USES, SPECIFICALLY, TREATMENT OF ONYCHOMYCOSIS
U-282	METHOD OF TREATING BACTERIAL INFECTIONS
U-283	METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020482 004	ACARBOSE;PRECOSE				I-252	SEP 29, 2001
						I-253	SEP 29, 2001
	020338 001	ADAPALENE;DIFFERIN	4717720	MAY 31, 2010	U-134		
			RE34440	MAR 31, 2010	U-275		
	020380 001	ADAPALENE;DIFFERIN	4717720	MAY 31, 2010	U-134		
			RE34440	MAY 31, 2010	U-275		
	020760 001	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE FREE	5164402	NOV 17, 2009	U-282		
			5763454	JUN 15, 2015	U-282		
	020760 002	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE FREE	5164402	NOV 17, 2009	U-282		
			5763454	JUN 15, 2015	U-282		
	020503 001	ALBUTEROL SULFATE;PROVENTIL-HFA				I-262	JUN 02, 2002
	019621 001	ALBUTEROL SULFATE;VENTOLIN	4594359	JUN 10, 2003			
>ADD>	020560 001	ALENDRONATE SODIUM;FOSAMAX				I-272	JUN 16, 2002
>ADD>	020560 002	ALENDRONATE SODIUM;FOSAMAX				I-272	JUN 16, 2002
>ADD>	020560 003	ALENDRONATE SODIUM;FOSAMAX				I-272	JUN 16, 2002
	020886 001	ALITRETINOIN;PANRETIN				ODE	FEB 02, 2006
						NCE	FEB 02, 2004
	020221 001	AMIFOSTINE;ETHYOL				ODE	JUN 24, 2006
	020508 001	AMMONIUM LACTATE;LAC-HYDRIN				PED	FEB 29, 2000
	021007 001	AMPRENAVIR;AGENERASE				NCE	APR 15, 2004
	021007 002	AMPRENAVIR;AGENERASE				NCE	APR 15, 2004
	021039 001	AMPRENAVIR;AGENERASE	5585397	DEC 17, 2013		NCE	APR 15, 2004
>ADD>	020702 001	ATORVASTATIN CALCIUM;LIPITOR	5969156	JUL 08, 2016			
>ADD>	020702 002	ATORVASTATIN CALCIUM;LIPITOR	5969156	JUL 08, 2016			
>ADD>	020702 003	ATORVASTATIN CALCIUM;LIPITOR	5969156	JUL 08, 2016			
	020500 001	ATOVAQUONE;MEPRON				ODE	JAN 05, 2006
						I-255	JAN 05, 2002
>ADD>	020746 001	BUDESONIDE;RHINOCORT AQUA				NDF	OCT 01, 2002
>ADD>	020746 002	BUDESONIDE;RHINOCORT AQUA				NDF	OCT 01, 2002
	020711 002	BUPROPION HYDROCHLORIDE;ZYBAN	5763493	AUG 12, 2013			
	020711 003	BUPROPION HYDROCHLORIDE;ZYBAN	5763493	AUG 12, 2013			
	020954 001	BUSULFAN;BUSULFEX	5430057	SEP 30, 2013	U-263	ODE	FEB 04, 2006
			5559148	MAY 24, 2015	U-264	NDF	FEB 04, 2002
	020793 001	CAFFEINE CITRATE;CAFCIT				NE	SEP 21, 2002
	020313 002	CALCITONIN, SALMON;MIACALCIN	5759565	JUN 02, 2015			
	020896 001	CAPECITABINE;XELODA	5472949	DEC 14, 2013	U-271		
			4966891	NOV 08, 2008	U-272		
	020896 002	CAPECITABINE;XELODA	5472949	DEC 14, 2013	U-271		
			4966891	NOV 08, 2008	U-272		
	020712 001	CARBAMAZEPINE;CARBATROL	5912013	JUN 15, 2016	U-277		
	020712 002	CARBAMAZEPINE;CARBATROL	5912013	JUN 15, 2016	U-277		
	020998 001	CELECOXIB;CELEBREX	5760068	JUN 02, 2015	U-19		
			5466823	NOV 30, 2013			
			5563165	NOV 30, 2013			
	020998 002	CELECOXIB;CELEBREX	5760068	JUN 02, 2015	U-19		
			5466823	NOV 30, 2013			
			5563165	NOV 30, 2013			
	020740 005	CERIVASTATIN SODIUM;BAYCOL	5006530	JAN 17, 2009		NS	MAY 24, 2002
			5177080	NOV 26, 2011			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020638 001	CIDOFOVIR;VISTIDE	5142051	JUN 26, 2010			
	020863 001	CILOSTAZOL;PLETAL	4277479	AUG 29, 2000		NCE	JAN 15, 2004
	020863 002	CILOSTAZOL;PLETAL	4277479	AUG 29, 2000		NCE	JAN 15, 2004
	019537 004	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	4670444	DEC 09, 2003	U-36		
			5286754	FEB 15, 2011			
	020767 001	CISAPRIDE MONOHYDRATE;PROPULSID QUICKSOLV	5648093	JUL 15, 2014			
	021041 001	CYTARABINE;DEPOCYT				ODE	APR 01, 2006
						NP	APR 01, 2002
	020287 001	DALTEPARIN SODIUM;FRAGMIN				I-263	MAY 25, 2002
						I-259	MAR 30, 2002
	020287 003	DALTEPARIN SODIUM;FRAGMIN				I-263	MAY 25, 2002
						I-259	MAR 30, 2002
	020287 004	DALTEPARIN SODIUM;FRAGMIN				I-263	MAY 25, 2002
						I-259	MAR 30, 2002
	017922 001	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	017922 002	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	017922 003	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	018938 001	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	018938 002	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	019955 001	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	019955 002	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
>ADD>	074752 001	DILTIAZEM HYDROCHLORIDE;CARTIA XT				PC	DEC 20, 1999
>ADD>	074752 003	DILTIAZEM HYDROCHLORIDE;CARTIA XT				PC	DEC 20, 1999
>ADD>	074752 004	DILTIAZEM HYDROCHLORIDE;CARTIA XT				PC	DEC 20, 1999
	020449 001	DOCETAXEL;TAXOTERE	4814470	MAY 14, 2010			
			5438072	NOV 22, 2013			
			5698582	JUL 03, 2012			
			5714512	JUL 03, 2012			
>ADD>	020931 001	DOFETILIDE;TIKOSYN				NCE	OCT 01, 2004
>ADD>	020931 002	DOFETILIDE;TIKOSYN				NCE	OCT 01, 2004
>ADD>	020931 003	DOFETILIDE;TIKOSYN				NCE	OCT 01, 2004
>ADD>	020869 001	DORZOLAMIDE HYDROCHLORIDE;COSOPT	4797413	APR 28, 2008			
>ADD>			4619939	OCT 28, 2003			
	020862 001	DOXERCALCIFEROL;HECTOROL	5602116	APR 03, 2115	U-278	NCE	JUN 09, 2004
			5707980	FEB 11, 2117	U-278		
	050718 001	DOXORUBICIN HYDROCHLORIDE;DOXIL				ODE	JUN 28, 2006
	020972 001	EFAVIRENZ;SUSTIVA	5811423	AUG 07, 2012	U-256		
			5519021	MAY 21, 2013			
			5663169	SEP 02, 2014	U-257		
	020972 002	EFAVIRENZ;SUSTIVA	5811423	AUG 07, 2012	U-256		
			5519021	MAY 21, 2013			
			5663169	SEP 02, 2014	U-257		
	020972 003	EFAVIRENZ;SUSTIVA	5519021	MAY 21, 2013			
			5663169	SEP 02, 2014	U-257		
			5811423	AUG 07, 2012	U-256		
>ADD>	050778 001	EPIRUBICIN HYDROCHLORIDE;ELLENCE				ODE	SEP 15, 2006
	020375 001	ESTRADIOL;CLIMARA				I-254	MAR 05, 2002
	020375 002	ESTRADIOL;CLIMARA				I-254	MAR 05, 2002
	020375 003	ESTRADIOL;CLIMARA				I-254	MAR 05, 2002

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020375 004	ESTRADIOL;CLIMARA	5223261	JUN 29, 2010		I-254	MAR 05, 2002
>ADD>	021040 002	ESTRADIOL;ORTHO-PREFEST				NP	OCT 22, 2002
	020908 001	ESTRADIOL;VAGIFEM				NP	MAR 26, 2002
	020992 002	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN				NP	MAR 24, 2002
	020992 003	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN				NP	MAR 24, 2002
	020527 001	ESTROGENS, CONJUGATED;PREMPRO 14/14	RE36247	MAY 02, 2006			
	020527 003	ESTROGENS, CONJUGATED;PREMPRO 14/14	4826831	MAY 02, 2006			
			5547948	JAN 17, 2015			
			RE36247	MAY 02, 2006			
>ADD>	021065 001	ETHINYL ESTRADIOL;FEMHRT	5208225	MAY 04, 2010	U-283	NP	OCT 15, 2002
>ADD>	021065 002	ETHINYL ESTRADIOL;FEMHRT	5208225	MAY 04, 2010	U-283	NP	OCT 15, 2002
>ADD>	021065 003	ETHINYL ESTRADIOL;FEMHRT	5208225	MAY 04, 2010	U-283	NP	OCT 15, 2002
>ADD>	020584 003	ETODOLAC;LODINE XL	4966768	OCT 30, 2007			
	020363 001	FAMCICLOVIR;FAMVIR	5246937	SEP 21, 2010	U-96		
	020363 003	FAMCICLOVIR;FAMVIR	5246937	SEP 21, 2010	U-96		
	020325 001	FAMOTIDINE;PEPCID AC	5854267	DEC 29, 2015	U-267		
>ADD>	020801 001	FAMOTIDINE;PEPCID AC	5667794	MAY 02, 2015			
			5854267	DEC 29, 2015	U-267		
			5075114	DEC 24, 2008			
	019304 002	FENOFIBRATE;TRICOR (MICRONIZED)	4895726	JAN 19, 2009			
	020747 001	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020747 002	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020747 003	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020747 004	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020747 005	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020747 006	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020955 001	FERRIC SODIUM GLUCONATE;FERRLECIT				NCE	FEB 18, 2004
	020625 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5855912	FEB 28, 2015			
			5738872	FEB 28, 2015			
	020788 001	FINASTERIDE;PROPECIA	5571817	NOV 05, 2013	U-259		
			5886184	NOV 19, 2012			
	020180 001	FINASTERIDE;PROSCAR	4760071	JUN 19, 2006	U-262		
			5886184	NOV 19, 2012			
			4377584	MAR 22, 2000	U-261		
			5942519	OCT 23, 2018	U-280		
	019452 001	FLUOCINOLONE ACETONIDE;DERMA-SMOOTHE/FS				I-265	AUG 18, 2002
	020101 001	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U-84		
					U-154		
	020974 001	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U-84		
			4626549	DEC 02, 2003	U-154		
			4314081	FEB 02, 2001			
	020974 002	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U-84		
			4626549	DEC 02, 2003	U-154		
			4314081	FEB 02, 2001			
	019958 001	FLUTICASONE PROPIONATE;CUTIVATE				I-267	JUN 17, 2002
	020121 001	FLUTICASONE PROPIONATE;FLONASE				I-258	DEC 11, 2001
	020882 001	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-106		
			5084479	JAN 02, 2010	U-258		
	020882 002	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-106		
			5084479	JAN 02, 2010	U-258		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021057 001	GANIRELIX ACETATE;ANTAGON	4801577	FEB 05, 2007		NCE	JUL 29, 2004
			5767082	JUN 16, 2015			
	020509 001	GEMCITABINE HYDROCHLORIDE;GEMZAR	4808614	MAY 15, 2010			
	020509 002	GEMCITABINE HYDROCHLORIDE;GEMZAR	4808614	MAY 15, 2010			
	020496 001	GLIMEPIRIDE;AMARYL	4379785	APR 06, 2005	U-118		
	020496 002	GLIMEPIRIDE;AMARYL	4379785	APR 06, 2005	U-118		
	020496 003	GLIMEPIRIDE;AMARYL	4379785	APR 06, 2005	U-118		
	020305 001	GRANISETRON HYDROCHLORIDE;KYTRIL				I-264	JUL 27, 2002
	020305 002	GRANISETRON HYDROCHLORIDE;KYTRIL				I-264	JUL 27, 2002
	020758 003	HYDROCHLOROTHIAZIDE;AVALIDE	5270317	MAR 20, 2011		NCE	SEP 30, 2002
	020491 001	IBUTILIDE FUMARATE;CORVERT				D-50	MAY 13, 2002
>ADD>	020723 001	IMIQUIMOD;ALDARA	4689338	AUG 25, 2009	U-172		
	021028 001	INSULIN HUMAN;VELOSULIN BR				NP	JUL 19, 2002
	020083 001	ITRACONAZOLE;SPORANOX	4791111	DEC 23, 2005			
	020657 001	ITRACONAZOLE;SPORANOX	4791111	DEC 23, 2005			
	020966 001	ITRACONAZOLE;SPORANOX	4791111	DEC 23, 2005			
			4267179	JUN 23, 2000			
	021066 001	KETOTIFEN FUMARATE;ZADITOR				NCE	JUL 02, 2004
	020564 001	LAMIVUDINE;EPIVIR	5905082	MAY 18, 2016			
	021003 001	LAMIVUDINE;EPIVIR-HBV	5047407	FEB 08, 2009		I-257	DEC 08, 2001
			5532246	JUL 02, 2013	U-250		
			5905082	MAY 18, 2016			
	021004 001	LAMIVUDINE;EPIVIR-HBV	5047407	FEB 08, 2009		I-257	DEC 08, 2001
			5532246	JUL 02, 2013	U-250		
	020764 001	LAMOTRIGINE;LAMICTAL CD				I-247	DEC 14, 2001
	020764 002	LAMOTRIGINE;LAMICTAL CD				I-247	DEC 14, 2001
	020764 003	LAMOTRIGINE;LAMICTAL CD				I-247	DEC 14, 2001
	020406 001	LANSOPRAZOLE;PREVACID				M-1	JUL 06, 2002
	020406 002	LANSOPRAZOLE;PREVACID				M-1	JUL 06, 2002
	020597 001	LATANOPROST;XALATAN	5296504	MAR 22, 2011	U-260		
			5422368	MAR 22, 2011	U-260		
			4599353	JUL 28, 2006	U-260		
	020517 002	LEUPROLIDE ACETATE;LUPRON DEPOT-4	4652441	NOV 01, 2004			
	020837 001	LEVALBUTEROL HYDROCHLORIDE;XOPENEX				NP	MAR 25, 2002
	020837 002	LEVALBUTEROL HYDROCHLORIDE;XOPENEX				NP	MAR 25, 2002
	020997 001	LEVOBUPIVACAINE HYDROCHLORIDE;CHIROCAINE	5708011	OCT 13, 2014	U-276		
	020997 002	LEVOBUPIVACAINE HYDROCHLORIDE;CHIROCAINE	5708011	OCT 13, 2014	U-276		
	020997 003	LEVOBUPIVACAINE HYDROCHLORIDE;CHIROCAINE	5708011	OCT 13, 2014	U-276		
	021045 001	LEVONORGESTREL;PLAN B				NP	JUL 28, 2002
	019941 001	LIDOCAINE;EMLA				I-260	MAR 11, 2002
	020612 001	LIDOCAINE;LIDODERM				ODE	MAR 19, 2006
	019777 006	LISINOPRIL;ZESTRIL	4374829	DEC 30, 2001			
	019643 002	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
	019643 003	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
	019643 004	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
>ADD>	021047 001	MENOTROPINS (FSH;LH);REPRONEX				NP	AUG 27, 2002
>ADD>	021047 002	MENOTROPINS (FSH;LH);REPRONEX				NP	AUG 27, 2002
>ADD>	020357 003	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				NCE	MAR 03, 2000
>ADD>	020357 004	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				NCE	MAR 03, 2000

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020357 005	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				NCE	MAR 03, 2000
	020969 001	METHOXSALEN;UVADEX	4845075	APR 11, 2009		NP	FEB 25, 2002
			5036102	JUL 30, 2008	U-273		
			4999375	MAR 12, 2008			
	020968 001	MICONAZOLE NITRATE;MONISTAT DUAL- PAK	5514698	MAR 21, 2014		NP	JUN 30, 2002
	020682 001	MIGLITOL;GLYSET	4639436	JAN 27, 2009	U-111		
	020682 002	MIGLITOL;GLYSET	4639436	JAN 27, 2009	U-111		
	020682 003	MIGLITOL;GLYSET	4639436	JAN 27, 2009	U-111		
	020717 001	MODAFINIL;PROVIGIL	4177290	MAR 09, 1999			
			5618845	OCT 06, 2014	U-255		
			4927855	MAY 22, 2007	U-255		
	020717 002	MODAFINIL;PROVIGIL	4177290	MAR 09, 1999			
			5618845	OCT 06, 2014	U-255		
			4927855	MAY 22, 2007	U-255		
	018612 003	NICOTINE POLACRILEX;NICORETTE (MINT)				NP*	DEC 23, 2001
	020066 003	NICOTINE POLACRILEX;NICORETTE (MINT)				NP*	DEC 23, 2001
	020385 001	NICOTINE;NICOTROL	5656255	AUG 12, 2014			
	021008 001	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5688530	NOV 18, 2014	U-268	ODE	NOV 25, 2005
			4395403	NOV 21, 2002	U-269		
			5538739	JUL 23, 2013			
			5639480	JUN 17, 2014			
			5922338	JUL 13, 2016			
			5922682	JUL 13, 2016			
	021008 002	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5688530	NOV 18, 2014	U-268	ODE	NOV 25, 2005
			4395403	NOV 21, 2002	U-269		
			5538739	JUL 23, 2013			
			5639480	JUN 17, 2014			
			5922338	JUL 13, 2016			
			5922682	JUL 13, 2016			
	021008 003	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5688530	NOV 18, 2014	U-268	ODE	NOV 25, 2005
			4395403	NOV 21, 2002	U-269		
			5538739	JUL 23, 2013			
			5639480	JUN 17, 2014			
			5922338	JUL 13, 2016			
			5922682	JUL 13, 2016			
	020103 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN				I-269	AUG 27, 2002
	020103 002	ONDANSETRON HYDROCHLORIDE;ZOFRAN				I-269	AUG 27, 2002
	020766 001	ORLISTAT;XENICAL				NCE	APR 23, 2004
	020897 001	OXYBUTYNIN CHLORIDE;DITROPAN XL	4783337	SEP 16, 2003		NP	DEC 16, 2001
			5674895	MAY 22, 2015			
			5082668	SEP 16, 2003			
			5840754	MAY 22, 2015			
			4612008	SEP 16, 2003			
			4519801	JUL 12, 2002			
			5912268	MAY 22, 2015			
	020897 002	OXYBUTYNIN CHLORIDE;DITROPAN XL	5840754	MAY 22, 2015		NP	DEC 16, 2001
			5674895	MAY 22, 2015			
			5082668	SEP 16, 2003			
			4783337	SEP 16, 2003			
			4612008	SEP 16, 2003			
			4519801	JUL 12, 2002			
			5912268	MAY 22, 2015			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020897 003	OXYBUTYNIN CHLORIDE;DITROPAN XL	5912268	MAY 22, 2015		NP	DEC 16, 2001
			4612008	SEP 16, 2003			
			4519801	JUL 12, 2002			
			5840754	MAY 22, 2015			
			5674895	MAY 22, 2015			
			5082668	SEP 16, 2003			
			4783337	SEP 16, 2003			
	020553 001	OXYCODONE HYDROCHLORIDE;OXYCONTIN	5508042	APR 16, 2013			
			5656295	FEB 05, 2008			
	020553 002	OXYCODONE HYDROCHLORIDE;OXYCONTIN	5508042	APR 16, 2013			
			5656295	FEB 05, 2008			
	020553 003	OXYCODONE HYDROCHLORIDE;OXYCONTIN	5508042	APR 16, 2013			
			5656295	FEB 05, 2008			
	020553 004	OXYCODONE HYDROCHLORIDE;OXYCONTIN	5508042	APR 16, 2013			
			5656295	FEB 05, 2008			
>ADD>	020262 001	PACLITAXEL;TAXOL				I-270	OCT 25, 2002
	020031 001	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
			5900423	MAY 19, 2015			
	020031 002	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
			5900423	MAY 19, 2015			
	020031 003	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
			5900423	MAY 19, 2015			
	020031 004	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
			5900423	MAY 19, 2015			
	020031 005	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
			5900423	MAY 19, 2015			
	020710 001	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
	020885 001	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
	020885 002	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
	020885 003	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
	020885 004	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
	020936 001	PAROXETINE HYDROCHLORIDE;PAXIL CR	5872132	MAY 19, 2015		NDF	FEB 16, 2002
			4839177	JUN 13, 2006			
			5422123	JUN 06, 2012			
			4721723	DEC 29, 2006			
			5900423	MAY 19, 2015			
	020936 002	PAROXETINE HYDROCHLORIDE;PAXIL CR	5872132	MAY 19, 2015		NDF	FEB 16, 2002
			4839177	JUN 13, 2006			
			5422123	JUN 06, 2012			
			4721723	DEC 29, 2006			
			5900423	MAY 19, 2015			
	021079 001	PEMIROLAST POTASSIUM;ALAMAST	5034230	DEC 23, 2008	U-184	PED	MAR 24, 2005
			5034230*PED	JUN 23, 2009	U-184	NCE	SEP 24, 2004
	021073 001	PIOGLITAZONE HYDROCHLORIDE;ACTOS	4444779	JUL 27, 1999		NCE	JUL 15, 2004
			4687777	JAN 17, 2006			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021073 002	PIOGLITAZONE HYDROCHLORIDE;ACTOS	4444779	JUL 27, 1999		NCE	JUL 15, 2004
			4687777	JAN 17, 2006			
	021073 003	PIOGLITAZONE HYDROCHLORIDE;ACTOS	4444779	JUL 27, 1999		NCE	JUL 15, 2004
			4687777	JAN 17, 2006			
	020698 001	POLYETHYLENE GLYCOL 3350;MIRALAX	5710183	JUL 14, 2015	U-265	NP	FEB 18, 2002
	019627 002	PROPOFOL;DIPRIVAN	5714520	MAR 22, 2015			
			5714520*PED	SEP 22, 2015			
			5731355	MAR 22, 2015	U-217		
			5731355*PED	SEP 22, 2015	U-217		
			5731356	MAR 22, 2015	U-218		
			5731356*PED	SEP 22, 2015	U-218		
			5908869	MAR 22, 2015	U-270		
			5908869*PED	SEP 22, 2015	U-270		
>ADD>	075102 001	PROPOFOL;PROPOFOL				PC	OCT 17, 1999
	020639 004	QUETIAPINE FUMARATE;SEROQUEL	4879288	MAR 20, 2007		NCE	SEP 26, 2002
	020973 002	RABEPRAZOLE SODIUM;ACIPHEX				NCE	AUG 19, 2004
>ADD>	020815 001	RALOXIFENE HYDROCHLORIDE;EVISTA				I-271	SEP 30, 2002
>ADD>	075094 001	RANITIDINE HYDROCHLORIDE;RANITIDINE HCL				PC	JAN 14, 2000
	020984 001	RAPACURONIUM BROMIDE;RAPLON	5418226	APR 14, 2013		NCE	AUG 18, 2004
	020984 002	RAPACURONIUM BROMIDE;RAPLON	5418226	APR 14, 2013		NCE	AUG 18, 2004
	020903 001	RIBAVIRIN;REBETOL	5914128	DEC 22, 2017			
	020272 007	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009	U-90	D-37	OCT 17, 2000
			4804663	DEC 29, 2007	U-90		
	020272 008	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U-90	D-37	OCT 17, 2000
			5158952	OCT 27, 2009	U-90		
	020680 001	RITONAVIR;NORVIR	5948436	SEP 13, 2013			
	020865 001	RIZATRIPTAN BENZOATE;MAXALT-MLT	5457895	OCT 01, 2013			
	020865 002	RIZATRIPTAN BENZOATE;MAXALT-MLT	5457895	OCT 01, 2013			
	021042 001	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266	NCE	MAY 20, 2004
			5691374	NOV 25, 2017			
	021042 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266	NCE	MAY 20, 2004
			5691374	NOV 25, 2017			
	021052 001	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266	NCE	MAY 20, 2004
			5691374	NOV 25, 2017			
	021052 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266	NCE	MAY 20, 2004
			5691374	NOV 25, 2017			
	021071 002	ROSIGLITAZONE MALEATE;AVANDIA				NCE	MAY 25, 2004
	021071 003	ROSIGLITAZONE MALEATE;AVANDIA				NCE	MAY 25, 2004
	021071 004	ROSIGLITAZONE MALEATE;AVANDIA				NCE	MAY 25, 2004
>ADD>	019766 001	SIMVASTATIN;ZOCOR				I-273	AUG 05, 2002
>ADD>	019766 002	SIMVASTATIN;ZOCOR				I-273	AUG 05, 2002
>ADD>	019766 003	SIMVASTATIN;ZOCOR				I-273	AUG 05, 2002
>ADD>	019766 004	SIMVASTATIN;ZOCOR				I-273	AUG 05, 2002
>ADD>	019766 005	SIMVASTATIN;ZOCOR				I-273	AUG 05, 2002
>ADD>	021083 001	SIROLIMUS;RAPAMUNE				NCE	SEP 15, 2004
	019640 005	SOMATROPIN, BIOSYNTHETIC;HUMATROPE				I-182	DEC 30, 1999
						ODE	DEC 30, 2003
	019640 006	SOMATROPIN, BIOSYNTHETIC;HUMATROPE				I-182	DEC 30, 1999
						ODE	DEC 30, 2003

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019640 007	SOMATROPIN, BIOSYNTHETIC;HUMATROPE				I-182	DEC 30, 1999
						ODE	DEC 30, 2003
	021012 001	TECHNETIUM TC-99M DEPREOTIDE;NEO TECT KIT				NCE	AUG 03, 2004
	021029 001	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
						ODE	AUG 11, 2006
	021029 002	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
						ODE	AUG 11, 2006
	021029 003	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
						ODE	AUG 11, 2006
	021029 004	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
						ODE	AUG 11, 2006
>ADD>	074823 001	TERAZOSIN HYDROCHLORIDE;TERAZOSIN HCL				PC	FEB 09, 2000
>ADD>	074823 002	TERAZOSIN HYDROCHLORIDE;TERAZOSIN HCL				PC	FEB 09, 2000
>ADD>	074823 003	TERAZOSIN HYDROCHLORIDE;TERAZOSIN HCL				PC	FEB 09, 2000
>ADD>	074823 004	TERAZOSIN HYDROCHLORIDE;TERAZOSIN HCL				PC	FEB 09, 2000
	020539 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4680291	JUL 14, 2004	U-281		
	020749 001	TERBINAFINE HYDROCHLORIDE;LAMISIL				NCE	DEC 30, 1999
	020980 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4680291	JUL 14, 2004	U-73	NCE	DEC 30, 1999
			4755534	DEC 30, 2006	U-73		
	020846 001	TERBINAFINE;LAMISIL				NP	APR 29, 2001
						NCE	DEC 30, 1999
	019762 001	TESTOSTERONE;TESTODERM	5840327	AUG 15, 2016			
	019762 002	TESTOSTERONE;TESTODERM	5840327	AUG 15, 2016			
	020646 005	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	OCT 07, 2008		NCE	SEP 30, 2002
			5354760	MAR 24, 2012			
	020912 001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5292756	MAY 14, 2012	U-230		
			5880136	SEP 27, 2010	U-254		
	020913 001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5292756	MAY 14, 2012	U-230		
			5880136	SEP 27, 2010	U-254		
	020505 001	TOPIRAMATE;TOPAMAX				I-266	JUL 23, 2002
>ADD>						I-274	OCT 01, 2002
	020505 002	TOPIRAMATE;TOPAMAX				I-266	JUL 23, 2002
>ADD>						I-274	OCT 01, 2002
	020505 003	TOPIRAMATE;TOPAMAX				I-266	JUL 23, 2002
>ADD>						I-274	OCT 01, 2002
>ADD>	020505 004	TOPIRAMATE;TOPAMAX				I-274	OCT 01, 2002
						I-266	JUL 23, 2002
>ADD>	020505 005	TOPIRAMATE;TOPAMAX				I-274	OCT 01, 2002
						I-266	JUL 23, 2002
>ADD>	020505 006	TOPIRAMATE;TOPAMAX				I-274	OCT 01, 2002
						I-266	JUL 23, 2002
>ADD>	020844 001	TOPIRAMATE;TOPAMAX SPRINKLE				I-274	OCT 01, 2002
						I-266	JUL 23, 2002
>ADD>	020844 002	TOPIRAMATE;TOPAMAX SPRINKLE				I-274	OCT 01, 2002
						I-266	JUL 23, 2002
>ADD>	020844 003	TOPIRAMATE;TOPAMAX SPRINKLE				I-274	OCT 01, 2002
						I-266	JUL 23, 2002
	020671 001	TOPOTECAN HYDROCHLORIDE;HYCAMTIN				I-256	NOV 30, 2001
	020759 001	TROVAFLOXACIN MESYLATE;TROVAN	5164402	NOV 17, 2009	U-282		
			5763454	JUN 15, 2015	U-282		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020759 002	TROVAFLOXACIN MESYLATE;TROVAN	5164402	NOV 17, 2009	U-282		
		5763454	JUN 15, 2015	U-282		
					NCE	SEP 17, 2001
020900 001	UREA, C-13;PYLORI-CHEK BREATH TEST				I-251	MAR 11, 2002
020699 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-251	MAR 11, 2002
020699 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-251	MAR 11, 2002
020699 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-251	MAR 11, 2002
020699 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-251	MAR 11, 2002
019614 004	VERAPAMIL HYDROCHLORIDE;VERELAN	4863742	JUN 19, 2007			
020943 001	VERAPAMIL HYDROCHLORIDE;VERELAN PM	4863742	JUN 19, 2007			
020943 002	VERAPAMIL HYDROCHLORIDE;VERELAN PM	4863742	JUN 19, 2007			
020943 003	VERAPAMIL HYDROCHLORIDE;VERELAN PM	4863742	JUN 19, 2007			
020547 001	ZAFIRLUKAST;ACCOLATE				I-268	SEP 17, 2002
020859 001	ZALEPLON;SONATA	4626538	JUN 23, 2003		NCE	AUG 13, 2004
020859 002	ZALEPLON;SONATA	4626538	JUN 23, 2003		NCE	AUG 13, 2004
021036 001	ZANAMIVIR;RELENZA	D379506	MAY 27, 2011		NCE	JUL 26, 2004
		4778054	OCT 18, 2005			
		4811731	JUL 29, 2006			
		5035237	JUL 30, 2008			
		5360817	NOV 01, 2011			
		5648379	JUL 15, 2014	U-274		
		4627432	DEC 09, 2003			

New 20th Edition

APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

20TH EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 8312

Charge your order. It's easy!

MasterCard VISA

☐ **Yes,** enter my subscription as follows:

__ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $90.00 per year.

The total cost of my order is $_____. Price includes regular shipping and handling and is subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐☐–☐☐
☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

_____
(Credit card expiration date)

Thank you for your order!

_____
Company or personal name

_____
Additional address/attention line

_____
Street address

_____
City, State, ZIP Code

(_____)_____
Daytime phone including area code

_____
Purchase Order No. (optional)

_____
(Authorizing Signature)

(10/98)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.

Approved drug products with therapeutic equivalence